<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ghrelin for the management of cachexia associated with cancer - Khatib, MN - 2018 | Cochrane Library</title> <meta content="Ghrelin for the management of cachexia associated with cancer - Khatib, MN - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012229.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ghrelin for the management of cachexia associated with cancer - Khatib, MN - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012229.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012229.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ghrelin for the management of cachexia associated with cancer" name="citation_title"/> <meta content="Mahalaqua Nazli Khatib" name="citation_author"/> <meta content="Datta Meghe Institute of Medical Sciences" name="citation_author_institution"/> <meta content="nazli.786@rediffmail.com" name="citation_author_email"/> <meta content="Anuraj H Shankar" name="citation_author"/> <meta content="Harvard University" name="citation_author_institution"/> <meta content="Richard Kirubakaran" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Abhay Gaidhane" name="citation_author"/> <meta content="Datta Meghe Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Shilpa Gaidhane" name="citation_author"/> <meta content="Datta Meghe Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Padam Simkhada" name="citation_author"/> <meta content="Liverpool John Moores University" name="citation_author_institution"/> <meta content="Zahiruddin Quazi Syed" name="citation_author"/> <meta content="Datta Meghe Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012229.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012229.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012229.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012229.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Body Composition [drug effects]; Cachexia [etiology]; *Eating; Ghrelin [*administration &amp; dosage, adverse effects]; Neoplasms [*complications]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012229.pub2&amp;doi=10.1002/14651858.CD012229.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012229\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012229\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","pl","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012229.pub2",title:"Ghrelin for the management of cachexia associated with cancer",firstPublishedDate:"Feb 28, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012229.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012229.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012229.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012229.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012229.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012229.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012229.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012229.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012229.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012229.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2724 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012229.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/appendices#CD012229-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ghrelin for the management of cachexia associated with cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Mahalaqua Nazli Khatib</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0005">Anuraj H Shankar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0006">Richard Kirubakaran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0007">Abhay Gaidhane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0008">Shilpa Gaidhane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0009">Padam Simkhada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information#CD012229-cr-0010">Zahiruddin Quazi Syed</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information/en#CD012229-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012229.pub2">https://doi.org/10.1002/14651858.CD012229.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012229-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012229-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012229-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012229-abs-0003">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012229-abs-0001" lang="en"> <section id="CD012229-sec-0001"> <h3 class="title" id="CD012229-sec-0001">Background</h3> <p>Cancer sufferers are amongst the most malnourished of all the patient groups. Studies have shown that ghrelin, a gut hormone can be a potential therapeutic agent for cachexia (wasting syndrome) associated with cancer. A variety of mechanisms of action of ghrelin in people with cancer cachexia have been proposed. However, safety and efficacy of ghrelin for cancer‐associated cachexia have not been systematically reviewed. The aim of this review was to assess whether ghrelin is associated with better food intake, body composition and survival than other options for adults with cancer cachexia. </p> </section> <section id="CD012229-sec-0002"> <h3 class="title" id="CD012229-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of ghrelin in improving food intake, body composition and survival in people with cachexia associated with cancer. </p> </section> <section id="CD012229-sec-0003"> <h3 class="title" id="CD012229-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE and Embase without language restrictions up to July 2017. We also searched for ongoing studies in trials registers, performed handsearching, checked bibliographic references of relevant articles and contacted authors and experts in the field to seek potentially relevant research. We applied no restrictions on language, date, or publication status. </p> </section> <section id="CD012229-sec-0004"> <h3 class="title" id="CD012229-sec-0004">Selection criteria</h3> <p>We included randomised controlled (parallel‐group or cross‐over) trials comparing ghrelin (any formulation or route of administration) with placebo or an active comparator in adults (aged 18 years and over) who met any of the international criteria for cancer cachexia. </p> </section> <section id="CD012229-sec-0005"> <h3 class="title" id="CD012229-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for eligibility. Two review authors then extracted data and assessed the risk of bias for individual studies using standard Cochrane methodology. For dichotomous variables, we planned to calculate risk ratio with 95% confidence intervals (CI) and for continuous data, we planned to calculate mean differences (MD) with 95% CI. We assessed the evidence using GRADE and created 'Summary of findings' tables. </p> </section> <section id="CD012229-sec-0006"> <h3 class="title" id="CD012229-sec-0006">Main results</h3> <p>We screened 926 individual references and identified three studies that satisfied the inclusion criteria. Fifty‐nine participants (37 men and 22 women) aged between 54 and 78 years were randomised initially, 47 participants completed the treatment. One study had a parallel design and two had a cross‐over design. The studies included people with a variety of cancers and also differed in the dosage, route of administration, frequency and duration of treatment. </p> <p>One trial, which compared ghrelin with placebo, found that ghrelin improved food intake (very low‐quality evidence) and had no adverse events (very low‐quality evidence). Due to unavailability of data we were unable to report on comparisons for ghrelin versus no treatment or alternative experimental treatment modalities, or ghrelin in combination with other treatments or ghrelin analogues/ghrelin mimetics/ghrelin potentiators. Two studies compared a higher dose of ghrelin with a lower dose of ghrelin, however due to differences in study designs and great diversity in the treatment provided we did not pool the results. In both trials, food intake did not differ between participants on higher‐dose and lower‐dose ghrelin. None of the included studies assessed data on body weight. One study reported higher adverse events with a higher dose as compared to a lower dose of ghrelin. </p> <p>All studies were at high risk of attrition bias and bias for size of the study. Risk of bias in other domains was unclear or low. </p> <p>We rated the overall quality of the evidence for primary outcomes (food intake, body weight, adverse events) as very low. We downgraded the quality of the evidence due to lack of data, high or unclear risk of bias of the studies and small study size. </p> </section> <section id="CD012229-sec-0007"> <h3 class="title" id="CD012229-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence to be able to support or refute the use of ghrelin in people with cancer cachexia. Adequately powered randomised controlled trials focusing on evaluation of safety and efficacy of ghrelin in people with cancer cachexia is warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012229-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012229-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012229-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012229-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012229-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012229-abs-0005">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012229-abs-0002" lang="en"> <h3>Ghrelin, a hunger hormone for management of cancer patients with loss of appetite and weight loss </h3> <p><b>Bottom line</b> </p> <p>There is no good evidence to support or reject the suggestion that ghrelin is useful in the management of cancer patients with loss of appetite and weight loss. There is insufficient evidence to recommend it for clinical practice. </p> <p><b>Background</b> </p> <p>Sixty to eighty percent of cancer patients suffer from loss of appetite and weight loss, which in turn is associated with decreased life expectancy and quality of life. Ghrelin, a hunger hormone is secreted by the stomach and other organs of the body. Studies have shown that ghrelin can be used in treatment for loss of appetite and weight loss in cancer patients. However, the effectiveness and safety of ghrelin in such people have not been assessed. In this review we set out to examine all evidence on the effectiveness and safety of ghrelin in improving appetite and body weight in cancer patients with loss of appetite and weight loss. </p> <p><b>Search date</b> </p> <p>The evidence is current to 20th July 2017.</p> <p><b>Study characteristics</b> </p> <p>We found three studies that recruited a total of 59 cancer patients (37 men and 22 women) aged between 54 and 78 years. Forty‐seven cancer patients completed the treatment. Studies differed in study design and included people with a variety of cancers. Studies also differed in dosage, route of injection, frequency and duration of treatment. One study compared ghrelin with a placebo while two studies compared different doses of ghrelin (higher dose with lower dose). Outcomes of interest to cancer patients with loss of appetite and weight loss, such as improvement in food intake and improvement in body weight, were not adequately reported. </p> <p>All three included studies were funded by government agencies. One study received an additional grant from a pharmaceutical company. </p> <p><b>Key findings</b> </p> <p>We found insufficient evidence that using ghrelin demonstrated differences in food intake. We found no evidence that using ghrelin alone or in combination made any difference to body weight. We could not reach any conclusions about its side effects. The limited amount of information means that we could not draw any conclusions. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of evidence from studies using four levels: high, moderate, low, or very low. High‐quality evidence means that we are very confident in the results. Very low‐quality evidence means that we are very uncertain about the results. The evidence in this review was of very low quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012229-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012229-sec-0091"></div> <h3 class="title" id="CD012229-sec-0092">Implications for practice</h3> <section id="CD012229-sec-0092"> <section id="CD012229-sec-0093"> <h5 class="title">For people with cancer cachexia</h5> <p>The amount and quality of evidence around the use of ghrelin for improving food intake and body weight in people with cancer cachexia is very low. This means that at present, treatment is based on clinical experience and advice from respected authorities. No judgement can be made about adverse events. </p> </section> <section id="CD012229-sec-0094"> <h5 class="title">For clinicians</h5> <p>We are not able to state the effect of ghrelin for improving food intake and body weight in people with cancer cachexia due to very low‐quality evidence. The low number and small size of the included studies, and the very low quality of the evidence means that this result should be viewed with very little confidence. No judgement can be made about adverse events. The findings of our review do not provide evidence to support or refute supplementation with ghrelin in people with cancer cachexia. There is insufficient evidence to recommend it for clinical practice. </p> </section> <section id="CD012229-sec-0095"> <h5 class="title">For policy makers</h5> <p>The small number of randomised controlled trials and the resulting paucity of information means that no conclusions concerning the use of ghrelin for improving food intake and body weight in people with cancer cachexia can be drawn. This review neither supports nor refutes the use of ghrelin for improving food intake and body weight in people with cancer cachexia. No judgement can be made about adverse events. </p> </section> <section id="CD012229-sec-0096"> <h5 class="title">For funders of the intervention</h5> <p>We identified only a small number of studies with small numbers of participants and insufficient data for analysis. The lack of evidence highlighted in this review implies that there is a need to fund and support suitable research for the treatment of cancer cachexia. </p> <p>We did not undertake cost‐effectiveness analysis.</p> </section> </section> <h3 class="title" id="CD012229-sec-0097">Implications for research</h3> <section id="CD012229-sec-0097"> <section id="CD012229-sec-0098"> <h5 class="title">General implications</h5> <p>We found that the current evidence base is comprised of studies that contain small numbers of participants in which there was a significant dropout rate. The lack of robust evidence regarding efficacy of ghrelin found in this review confirms the need to design high‐quality and clinically relevant research on this topic. The challenge is to develop trials examining clinically meaningful, patient‐centred outcomes. </p> </section> <section id="CD012229-sec-0099"> <h5 class="title">Design</h5> <p>Very few studies combined with small size, cross‐over design and consequent attrition, confirms the need for further adequately powered, methodologically sound, large, randomised controlled trials with long‐term follow‐up to ensure adequate data after the effect of attrition due to various causes. Studies with a cross‐over design often have significant attrition, therefore parallel‐group designs may be preferable. Improved quality in study designs and improvement in reporting of outcomes would add to the confidence in our estimates. </p> </section> <section id="CD012229-sec-0100"> <h5 class="title">Measurement (endpoints)</h5> <p>There is a need for randomised controlled trials with long‐term follow‐up focusing on evaluation of safety and efficacy of ghrelin in people with cancer cachexia. Trials looking at key endpoints including food intake, body weight and adverse events are warranted. Several outcomes for different doses, routes and duration of ghrelin have been evaluated through single trials, and independent replication of these studies is desirable. Cost‐effectiveness analysis can also be taken up for evaluating improvements in this condition relative to the costs of other interventions. </p> </section> <section id="CD012229-sec-0101"> <h5 class="title">Other</h5> <p>The study design of choice is the prospective randomised trial, but other pragmatic designs may be worth considering. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012229-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012229-sec-0008"></div> <div class="table" id="CD012229-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ghrelin compared to placebo for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin compared to placebo for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cachexia associated with cancer </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study reported, "31% increase in energy intake with ghrelin infusion"</p> <p>Too few data to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No data available.</p> <p>No evidence to support or refute the use of ghrelin in people with cancer cachexia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study reported, "No side effects were observed"</p> <p>Too few data and number of events too small to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size.<br/><sup>2</sup>Downgraded twice for imprecision due to sparse data and low participant numbers.<br/><sup>3</sup>Downgraded three times: in circumstances where there were no data reported for an outcome, we reported the level of evidence as very low with no evidence to support or refute the use of ghrelin in people with cancer cachexia.<br/><sup>4</sup>Downgraded twice for imprecision due to sparse data, low participant numbers and number of events too small to be meaningful. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012229-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin<br/><b>Comparison</b>: alternative experimental treatment modality (like appetisers, nutritional supplements, etc.) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alternative experimental treatment modality</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012229-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin in combination with other treatments<br/><b>Comparison</b>: ghrelin treatment alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin treatment alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin in combination with other treatments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012229-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : higher‐dose ghrelin<br/><b>Comparison</b>: lower‐dose ghrelin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lower‐dose ghrelin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with higher‐dose ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Too few data to be meaningful</p> <p>Because of the differences in study design and diversity in the treatment provided we did not pool results in a meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Too few data to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval <b>N/A</b>: not applicable </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size.<br/><sup>2</sup>Downgraded twice for imprecision due to low participant numbers.<br/><sup>3</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012229-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012229-sec-0009"></div> <p>This review is partly based on suggested wording from Cochrane Pain, Palliative and Supportive Care (PaPaS). </p> <section id="CD012229-sec-0010"> <h3 class="title" id="CD012229-sec-0010">Description of the condition</h3> <p>Cancer and its co‐morbidities like cancer cachexia (muscle wasting) have afflicted humans for centuries and still continue to be a major public health problem that profoundly affects more than 1.6 million people each year (<a href="./references#CD012229-bbs2-0084" title="National Cancer Institute, NIH. Cancer Trends Progress Report. progressreport.cancer.gov March 2015 (accessed 26 July 2017).">National Cancer Institute 2015</a>). People suffering from cancer are amongst the most malnourished of all the patient groups (<a href="./references#CD012229-bbs2-0094" title="RyanAM , PowerDG , DalyL , CushenSJ , Ni BhuachallaE , PradoCM . Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. In: Nutrition Society. 2016:1-13. [PMID: 26786393]">Ryan 2016</a>). It has been estimated that cachexia affects 60% to 80% of all advanced cancer patients (<a href="./references#CD012229-bbs2-0017" title="BaracosVE . Pitfalls in defining and quantifying cachexia. Journal of Cachexia, Sarcopenia and Muscle2011;2(2):71-3. [PMID: 21766051]">Baracos 2011</a>) and more than 30% of patients die due to cachexia (<a href="./references#CD012229-bbs2-0113" title="vonHaehlingS , AnkerSD . Cachexia as major underestimated unmet medical need: facts and numbers. International Journal of Cardiology2012;161(3):121-3. [PMID: 23084543]">von Haehling 2012</a>). Cancer cachexia is commonly associated with poor quality of life (<a href="./references#CD012229-bbs2-0039" title="FearonKCH , GlassD , GuttridgeDC . Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabolism2012;16(2):153-66.">Fearon 2012</a>; <a href="./references#CD012229-bbs2-0073" title="LoumayeA , Thissen J-P. Biomarkers of cancer cachexia. Clinical Biochemistry2017;pii: S0009-9120(17):30427-7. [DOI: 10.1016/j.clinbiochem.2017.07.011. [Epub ahead of print]]">Loumaye 2017</a>; <a href="./references#CD012229-bbs2-0109" title="UtechAE , TadrosEM , HayesTG , GarciaJM . Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. Journal of Cachexia, Sarcopenia and Muscle2012;3(4):245-51. [PMID: 22648739]">Utech 2012</a>). </p> <p>Cancer cachexia is defined as "a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment" (<a href="./references#CD012229-bbs2-0038" title="FearonK , StrasserF , AnkerSD , BosaeusI , BrueraE , FainsingerRL , et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology2011;12(5):489-95. [PMID: 21296615]">Fearon 2011</a>). Cachexia syndrome can develop progressively, through stages of pre‐cachexia to cachexia to refractory cachexia (<a href="./references#CD012229-bbs2-0038" title="FearonK , StrasserF , AnkerSD , BosaeusI , BrueraE , FainsingerRL , et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology2011;12(5):489-95. [PMID: 21296615]">Fearon 2011</a>). The incidence of cancer cachexia varies according to tumor type (<a href="./references#CD012229-bbs2-0105" title="TeunissenSC , WeskerW , KruitwagenC , De HaesHC , VoestEE , De GraeffA . Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management2007;34(1):94-104. [PMID: 17509812]">Teunissen 2007</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>; <a href="./references#CD012229-bbs2-0101" title="SunL , QuanXQ , YuS . An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutrition and Cancer2015;67(7):1056-62. [PMID: 26317149]">Sun 2015</a>). The prevalence of cachexia is highest in people with pancreatic cancer (88.9%), followed by gastric cancer (76.5% to 87%) and oesophageal cancer (52.9%) (<a href="./references#CD012229-bbs2-0101" title="SunL , QuanXQ , YuS . An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutrition and Cancer2015;67(7):1056-62. [PMID: 26317149]">Sun 2015</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). The frequency of weight loss is lowest in patients with breast cancer, sarcomas, non‐Hodgkin's lymphoma and acute nonlymphocytic leukaemia (<a href="./references#CD012229-bbs2-0105" title="TeunissenSC , WeskerW , KruitwagenC , De HaesHC , VoestEE , De GraeffA . Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management2007;34(1):94-104. [PMID: 17509812]">Teunissen 2007</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). Although certain tumor types are more commonly associated with cachexia, even with the same tumor type there are variations in the extent to which people exhibit cachexia (<a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). Cachexia can be a presenting symptom in a majority of people with advanced cancer, mainly those with hepatic, lung, or bone metastasis and primary cancers of the lung, cervix or head and neck (<a href="./references#CD012229-bbs2-0078" title="MendesMCS , PimentelGD , CostaFO , CarvalheiraJBC . Molecular and neuroendocrine mechanisms of cancer cachexia. Journal of Endocrinology2015;226(3):R29-43.">Mendes 2015</a>). Cancer patients with muscle wasting are less able to tolerate chemotherapy, have poor treatment outcomes, and have shorter survival (<a href="./references#CD012229-bbs2-0025" title="CrawfordJ . Cachexia. Journal of Thoracic Oncology2015;2:S158.">Crawford 2015</a>). </p> <p>Extensive research has been carried out to understand the complex pathophysiology of cachexia associated with cancer (<a href="./references#CD012229-bbs2-0018" title="Bennani-BaitiN , DavisMP . Cytokines and cancer anorexia cachexia syndrome. American Journal of Hospice &amp; Palliative Care2008;25(5):407-11. [PMID: 18403577]">Bennani‐Baiti 2008</a>; <a href="./references#CD012229-bbs2-0078" title="MendesMCS , PimentelGD , CostaFO , CarvalheiraJBC . Molecular and neuroendocrine mechanisms of cancer cachexia. Journal of Endocrinology2015;226(3):R29-43.">Mendes 2015</a>; <a href="./references#CD012229-bbs2-0087" title="OhnumaT , AdigunR . Cancer, Anorexia and Cachexia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2017.">Ohnuma 2017</a>; <a href="./references#CD012229-bbs2-0089" title="PennaF , BusquetsS , ArgilesJM . Experimental cancer cachexia: evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology2016;54:20-7. [DOI: 10.1016/j.semcdb.2015.09.002] [PMID: 26343953]">Penna 2016</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). However, precise molecular mechanisms of cancer cachexia still remain poorly characterised (<a href="./references#CD012229-bbs2-0073" title="LoumayeA , Thissen J-P. Biomarkers of cancer cachexia. Clinical Biochemistry2017;pii: S0009-9120(17):30427-7. [DOI: 10.1016/j.clinbiochem.2017.07.011. [Epub ahead of print]]">Loumaye 2017</a>). The pathogenesis of cancer anorexia is multifactorial. It is suggested to be the result of tumour‐host interactions (<a href="./references#CD012229-bbs2-0018" title="Bennani-BaitiN , DavisMP . Cytokines and cancer anorexia cachexia syndrome. American Journal of Hospice &amp; Palliative Care2008;25(5):407-11. [PMID: 18403577]">Bennani‐Baiti 2008</a>). Anorexia, anaemia, asthenia, inflammation, altered hormonal homeostasis, energy imbalance, perturbations in proinflammatory cytokines, impaired immunity and several cancer‐related metabolic changes (like negative protein balance and increased lipolysis) leading to significant weight loss have been attributed to the pathogenesis of cancer cachexia (<a href="./references#CD012229-bbs2-0018" title="Bennani-BaitiN , DavisMP . Cytokines and cancer anorexia cachexia syndrome. American Journal of Hospice &amp; Palliative Care2008;25(5):407-11. [PMID: 18403577]">Bennani‐Baiti 2008</a>; <a href="./references#CD012229-bbs2-0078" title="MendesMCS , PimentelGD , CostaFO , CarvalheiraJBC . Molecular and neuroendocrine mechanisms of cancer cachexia. Journal of Endocrinology2015;226(3):R29-43.">Mendes 2015</a>; <a href="./references#CD012229-bbs2-0088" title="PennaF , CostamagnaD , FanzaniA , BonelliG , BaccinoFM , CostelliP . Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PloS one2010;5(10):e13604. [PMID: 21048967]">Penna 2010</a>; <a href="./references#CD012229-bbs2-0098" title="StephensNA , SkipworthRJ , FearonKC . Cachexia, survival and the acute phase response. Current Opinion in Supportive and Palliative Care2008;2(4):267-74. [PMID: 19060563]">Stephens 2008</a>). Therapies for cancer, such as chemotherapy, surgery and radiotherapy, also cause anorexia, muscle atrophy and weight loss (<a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>; <a href="./references#CD012229-bbs2-0045" title="GarciaJM , Garcia-TouzaM , HijaziRA , TaffetG , EpnerD , MannD , et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism2005;90(5):2920-6. [PMID: 15713718]">Garcia 2005</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). Deregulation of control of energy expenditure and hunger/satiety by the hypothalamus promotes cachexia in cancer patients (<a href="./references#CD012229-bbs2-0078" title="MendesMCS , PimentelGD , CostaFO , CarvalheiraJBC . Molecular and neuroendocrine mechanisms of cancer cachexia. Journal of Endocrinology2015;226(3):R29-43.">Mendes 2015</a>). A discrepancy between anabolic and catabolic pathways mediated by chronic inflammation can cause muscle wasting in people with cancer cachexia (<a href="./references#CD012229-bbs2-0075" title="MadedduC , MantovaniG , GramignanoG , AstaraG , MaccioA . Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncology2015;[Epub ahead of print]. [PMID: 26376740]">Madeddu 2015a</a>). Depletion of adipose tissue as well as skeletal muscle mass with relative preservation of non‐muscle protein compartment can contribute to weight loss in cancer patients (<a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). Studies suggest that the tumour cells secrete certain humoral factors that promote central and peripheral‐mediated cancer cachexia (<a href="./references#CD012229-bbs2-0099" title="StewartGD , SkipworthRJ , FearonKC . Cancer cachexia and fatigue. Clinical Medicine2006;6(2):140-3. [PMID: 16688969]">Stewart 2006</a>; <a href="./references#CD012229-bbs2-0087" title="OhnumaT , AdigunR . Cancer, Anorexia and Cachexia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2017.">Ohnuma 2017</a>). Cachectic factors (like activin and proteolysis‐inducing factor) secreted by tumour cells decrease the synthesis and increase the breakdown of muscle proteins, and thereby induce sarcopenia (<a href="./references#CD012229-bbs2-0099" title="StewartGD , SkipworthRJ , FearonKC . Cancer cachexia and fatigue. Clinical Medicine2006;6(2):140-3. [PMID: 16688969]">Stewart 2006</a>). Excretion of cytokines and lipid‐mobilising factors may contribute to depletion of adipose tissue (<a href="./references#CD012229-bbs2-0099" title="StewartGD , SkipworthRJ , FearonKC . Cancer cachexia and fatigue. Clinical Medicine2006;6(2):140-3. [PMID: 16688969]">Stewart 2006</a>). Inflammation induced by host‐derived and tumor‐derived factors seems to be vital in the development of cancer cachexia (<a href="./references#CD012229-bbs2-0073" title="LoumayeA , Thissen J-P. Biomarkers of cancer cachexia. Clinical Biochemistry2017;pii: S0009-9120(17):30427-7. [DOI: 10.1016/j.clinbiochem.2017.07.011. [Epub ahead of print]]">Loumaye 2017</a>). Tumor cells secrete pro‐inflammatory factors that promote cachexia by signalling anorexia, wasting of muscles and atrophy of adipose tissue (<a href="./references#CD012229-bbs2-0023" title="ChenJL , WaltonKL , QianH , ColganTD , HaggA , WattMJ , et al. Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Research2016;76(18):5372-82.">Chen 2016</a>; <a href="./references#CD012229-bbs2-0057" title="JohnsN , StephensNA , FearonKCH . Muscle wasting in cancer. The International Journal of Biochemistry &amp; Cell Biology2013;45(10):2215-29.">Johns 2013</a>; <a href="./references#CD012229-bbs2-0073" title="LoumayeA , Thissen J-P. Biomarkers of cancer cachexia. Clinical Biochemistry2017;pii: S0009-9120(17):30427-7. [DOI: 10.1016/j.clinbiochem.2017.07.011. [Epub ahead of print]]">Loumaye 2017</a>). Release of inflammatory cytokines like TNF‐alpha (cachexin or cachectin), interferon gamma, interleukin‐6 and angiotensin II also have a role in cancer cachexia (<a href="./references#CD012229-bbs2-0018" title="Bennani-BaitiN , DavisMP . Cytokines and cancer anorexia cachexia syndrome. American Journal of Hospice &amp; Palliative Care2008;25(5):407-11. [PMID: 18403577]">Bennani‐Baiti 2008</a>; <a href="./references#CD012229-bbs2-0057" title="JohnsN , StephensNA , FearonKCH . Muscle wasting in cancer. The International Journal of Biochemistry &amp; Cell Biology2013;45(10):2215-29.">Johns 2013</a>; <a href="./references#CD012229-bbs2-0087" title="OhnumaT , AdigunR . Cancer, Anorexia and Cachexia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2017.">Ohnuma 2017</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). </p> <p>As cachexia progresses, wasting of skeletal muscles limits mobility and thereby leads to poor quality of life, which in turn pushes cancer patients towards isolation and depression (<a href="./references#CD012229-bbs2-0099" title="StewartGD , SkipworthRJ , FearonKC . Cancer cachexia and fatigue. Clinical Medicine2006;6(2):140-3. [PMID: 16688969]">Stewart 2006</a>; <a href="./references#CD012229-bbs2-0114" title="WatanabeS , BrueraE . Anorexia and cachexia, asthenia, and lethargy. Hematology/Oncology Clinics of North America1996;10(1):189-206. [PMID: 8821567]">Watanabe 1996</a>; <a href="./references#CD012229-bbs2-0115" title="WindsorJA , HillGL . Risk factors for postoperative pneumonia. The importance of protein depletion. Annals of Surgery1988;208(2):209-14. [PMID: 3401064]">Windsor 1988</a>). Patients as well as family members, especially caregivers and healthcare professionals often suffer from depression as they try to palliate the symptoms (<a href="./references#CD012229-bbs2-0084" title="National Cancer Institute, NIH. Cancer Trends Progress Report. progressreport.cancer.gov March 2015 (accessed 26 July 2017).">National Cancer Institute 2015</a>; <a href="./references#CD012229-bbs2-0092" title="ReidJ , MillsM , CantwellM , CardwellCR , MurrayLJ , DonnellyM . Thalidomide for managing cancer cachexia. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD008664. [DOI: 10.1002/14651858.CD008664.pub2]">Reid 2012</a>). Although cancer cachexia is associated with increased mortality and poor quality of life, treatment options for the condition are limited (<a href="./references#CD012229-bbs2-0089" title="PennaF , BusquetsS , ArgilesJM . Experimental cancer cachexia: evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology2016;54:20-7. [DOI: 10.1016/j.semcdb.2015.09.002] [PMID: 26343953]">Penna 2016</a>). It has been proposed that multimodal strategies with anabolic focus ensuring sufficient energy and protein intake, pharmacological treatments, and non‐pharmacological therapies like physical training initiated early in the disease may provide benefit to people with cancer cachexia (<a href="./references#CD012229-bbs2-0010" title="AaproM , ArendsJ , BozzettiF , FearonK , GrunbergSM , HerrstedtJ , et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Annals of Oncology2014;25(8):1492-9. [PMID: 24569913]">Aapro 2014</a>; <a href="./references#CD012229-bbs2-0012" title="AndersonLJ , AlbrechtED , GarciaJM . Update on management of cancer-related cachexia. Current Oncology Reports2017;19(1):3.">Anderson 2017</a>; <a href="./references#CD012229-bbs2-0014" title="ArgilésJM , Lopez-SorianoFJ , StemmlerB , BusquetsS . Novel targeted therapies for cancer cachexia. The Biochemical Journal2017;474(16):2663-78. [DOI: 10.1042/BCJ20170032] [PMID: 28751550 ]">Argilés 2017</a>; <a href="./references#CD012229-bbs2-0074" title="LuciaS , EspositoM , Rossi FanelliF , MuscaritoliM . Cancer cachexia: from molecular mechanisms to patient's care. Critical Reviews in Oncogenesis2012;17(3):315-21. [PMID: 22831162]">Lucia 2012</a>; <a href="./references#CD012229-bbs2-0075" title="MadedduC , MantovaniG , GramignanoG , AstaraG , MaccioA . Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncology2015;[Epub ahead of print]. [PMID: 26376740]">Madeddu 2015a</a>). </p> </section> <section id="CD012229-sec-0011"> <h3 class="title" id="CD012229-sec-0011">Description of the intervention</h3> <p>As cancer cachexia is associated with complex pathophysiological processes, pharmacologic treatment with potential orexigenic, anabolic and anti‐inflammatory effects should be targeted to counter this condition (<a href="./references#CD012229-bbs2-0076" title="MadedduC , MantovaniG , GramignanoG , MaccioA . Advances in pharmacologic strategies for cancer cachexia. Expert Opinion on Pharmacotherapy2015;16(14):2163-77. [PMID: 26330024]">Madeddu 2015b</a>). Caloric supplementation or appetite stimulants like megestrol acetate, medroxyprogesterone acetate (MPA), cyproheptadine, marijuana, and corticosteroids such as dexamethasone, prednisolone and methylprednisolone have been used for enhancing appetite in people with cancer (<a href="./references#CD012229-bbs2-0038" title="FearonK , StrasserF , AnkerSD , BosaeusI , BrueraE , FainsingerRL , et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology2011;12(5):489-95. [PMID: 21296615]">Fearon 2011</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). However, these interventions have limited efficacy. No definitive pharmacological treatment is available to address the relevant components of the cancer cachexia syndrome (<a href="./references#CD012229-bbs2-0035" title="EspositoA , CriscitielloC , GelaoL , PravettoniG , LocatelliM , MinchellaI , et al. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treatment Reviews2015;41(9):793-7. [PMID: 26386985]">Esposito 2015</a>). Studies in animals and humans have shown that ghrelin, a gut hormone can be a potential therapeutic agent for treatment of cachexia associated with cancer (<a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>; <a href="./references#CD012229-bbs2-0053" title="HatanakaM , KonishiM , IshidaJ , SaitoM , SpringerJ . Novel mechanism of ghrelin therapy for cachexia. Journal of Cachexia, Sarcopenia and Muscle2015;6(4):393. [DOI: 10.1002/jcsm.12084]">Hatanaka 2015</a>; <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>; <a href="./references#CD012229-bbs2-0108" title="TsubouchiH , YanagiS , MiuraA , MatsumotoN , KangawaK , NakazatoM . Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology2014;743:1-10. [PMID: 25257464]">Tsubouchi 2014</a>). </p> <p>Ghrelin, a 28‐amino acid peptide hormone, is an endogenous ligand for growth hormone secretagogue receptor (<a href="./references#CD012229-bbs2-0063" title="KhatibMN , GaidhaneS , GaidhaneAM , KhatibM , SimkhadaP , GodeD , et al. Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion. Journal of Clinical and Diagnostic Research2014;8(8):MC13-7. [PMID: 25302229]">Khatib 2014f</a>; <a href="./references#CD012229-bbs2-0067" title="KojimaM , HosodaH , DateY , NakazatoM , MatsuoH , KangawaK . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature1999;402(6762):656-60.">Kojima 1999</a>). This orexigenic gut hormone is primarily secreted by the endocrine X/A‐like cells of the stomach mucosa and also by intestinal mucosa, kidney, placenta, arcuate nucleus of the hypothalamus, pituitary gland, pancreatic islets, and other tissues (<a href="./references#CD012229-bbs2-0051" title="GualilloO , CaminosJ , BlancoM , Garcìa-CaballeroT , KojimaM , KangawaK , et al. Ghrelin, a novel placental-derived hormone. Endocrinology2001;142(2):788-94.">Gualillo 2001</a>; <a href="./references#CD012229-bbs2-0065" title="KhatibMN , GaidhaneS , GaidhaneAM , SimkhadaP , ZahiruddinQS . Ghrelin-O-acyl-transferase (GOAT) as a novel metabolic regulatory enzyme. Journal of Clinical and Diagnostic Research2015;9(2):LE01-5. [PMID: 25859472]">Khatib 2015b</a>; <a href="./references#CD012229-bbs2-0067" title="KojimaM , HosodaH , DateY , NakazatoM , MatsuoH , KangawaK . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature1999;402(6762):656-60.">Kojima 1999</a>; <a href="./references#CD012229-bbs2-0069" title="KorbonitsM , BustinSA , KojimaM , JordanS , AdamsEF , LoweDG , et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. The Journal of Clinical Endocrinology and Metabolism2001;86(2):881-7.">Korbonits 2001</a>; <a href="./references#CD012229-bbs2-0081" title="MoriK , YoshimotoA , TakayaK , HosodaK , AriyasuH , YahataK , et al. Kidney produces a novel acylated peptide, ghrelin. FEBS Letters2000;486(3):213-6.">Mori 2000</a>; <a href="./references#CD012229-bbs2-0110" title="Van der LelyAJ , TschöpM , HeimanML , GhigoE . Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine Reviews2004;25(3):426-57.">Van der Lely 2004</a>; <a href="./references#CD012229-bbs2-0112" title="VolanteM , AllìaE , GugliottaP , FunaroA , BroglioF , DeghenghiR , et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. The Journal of Clinical Endocrinology and Metabolism2002;87(3):1300-8.">Volante 2002</a>). It circulates in the blood stream under fasting conditions, indicating that it transmits the hunger signals from periphery to the central nervous system (<a href="./references#CD012229-bbs2-0068" title="KojimaM , KangawaK . Structure and function of ghrelin. Results and Problems in Cell Differentiation2008;46:89-115.">Kojima 2008</a>). Ghrelin plays an important role in regulation of release of growth hormone and energy homeostasis (<a href="./references#CD012229-bbs2-0060" title="KhatibMN , KhatibM , GaidhaneS , GaidhaneA , QuaziSZ . Ghrelin for regulating appetite and energy balance: a systematic review. National Journal of Physiology, Pharmacy and Pharmacology2014;4(3):101-5. [DOI: 10.5455/njppp.2014.4.230420141]">Khatib 2014c</a>; <a href="./references#CD012229-bbs2-0067" title="KojimaM , HosodaH , DateY , NakazatoM , MatsuoH , KangawaK . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature1999;402(6762):656-60.">Kojima 1999</a>; <a href="./references#CD012229-bbs2-0068" title="KojimaM , KangawaK . Structure and function of ghrelin. Results and Problems in Cell Differentiation2008;46:89-115.">Kojima 2008</a>). It has the potential to increase body weight and body composition through increased appetite, increased growth hormone (GH) secretion, prevention of muscle catabolism, promotion of gut motility, stimulation of gastric acid secretion, and regulation of metabolism (<a href="./references#CD012229-bbs2-0021" title="Chen C-Y, Tsai C-Y. Ghrelin and motilin in the gastrointestinal system. Current Pharmaceutical Design2012;18(31):4755-65.">Chen 2012</a>; <a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>; <a href="./references#CD012229-bbs2-0030" title="DeBoerMD , ZhuX , LevasseurP , MeguidM , SuzukiS , InuiA , et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology2007;148(6):3004-12. [PMID: 17347304]">DeBoer 2007</a>; <a href="./references#CD012229-bbs2-0041" title="FujitsukaN , AsakawaA , HayashiM , SameshimaM , AmitaniH , KojimaS , et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biological Psychiatry2009;65(9):748-59. [PMID: 19058784]">Fujitsuka 2009</a>; <a href="./references#CD012229-bbs2-0042" title="FujitsukaN , AsakawaA , UezonoY , MinamiK , YamaguchiT , NiijimaA , et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translational Psychiatry2011;1:e23.">Fujitsuka 2011</a>; <a href="./references#CD012229-bbs2-0045" title="GarciaJM , Garcia-TouzaM , HijaziRA , TaffetG , EpnerD , MannD , et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism2005;90(5):2920-6. [PMID: 15713718]">Garcia 2005</a>; <a href="./references#CD012229-bbs2-0048" title="GarciaJM , FriendJ , AllenS . Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer2013;21(1):129-37. [PMID: 22699302]">Garcia 2013</a>; <a href="./references#CD012229-bbs2-0058" title="KhatibMN , GaidhaneS , GaidhaneA , SyedZQ . Role of ghrelin in regulation of growth hormone secretion by ghrelin-pituitary-GH axis. International Journal of Medical Science and Public Health2014;3(4):425-9. [DOI: 10.5455/ijmsph.2014.250120141]">Khatib 2014a</a>; <a href="./references#CD012229-bbs2-0061" title="KhatibMN , GodeD , SimkhadaP , AghoK , GaidhaneS , SaxenaD , et al. Somatotropic and cardio-protective effects of ghrelin in experimental models of heart failure: a systematic review. Annals of Tropical Medicine and Public Health2014;7(1):30-42. [DOI: 10.4103/1755-6783.145008]">Khatib 2014d</a>; <a href="./references#CD012229-bbs2-0063" title="KhatibMN , GaidhaneS , GaidhaneAM , KhatibM , SimkhadaP , GodeD , et al. Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion. Journal of Clinical and Diagnostic Research2014;8(8):MC13-7. [PMID: 25302229]">Khatib 2014f</a>; <a href="./references#CD012229-bbs2-0062" title="KhatibMN , GaidhaneS , SimkhadaP , GaidhaneA , QuaziSZ . Cardiovascular effects of ghrelin in heart failure: a systematic review. International Journal of Medical Science and Public Health2014;3(6):756-63. [DOI: 10.5455/ijmsph.2014.060420141]">Khatib 2014e</a>; <a href="./references#CD012229-bbs2-0066" title="KlokMD , JakobsdottirS , DrentML . The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity Reviews2007;8(1):21-34. [PMID: 17212793]">Klok 2007</a>; <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0083" title="MüllerTD , NogueirasR , AndermannML , AndrewsZB , AnkerSD , ArgenteJ , et al. Ghrelin. Mol Metab2015;4(6):437–60. [DOI: 10.1016/j.molmet.2015.03.005]">Müller 2015</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>; <a href="./references#CD012229-bbs2-0108" title="TsubouchiH , YanagiS , MiuraA , MatsumotoN , KangawaK , NakazatoM . Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology2014;743:1-10. [PMID: 25257464]">Tsubouchi 2014</a>; <a href="./references#CD012229-bbs2-0116" title="WrenAM , SealLJ , CohenMA , BrynesAE , FrostGS , MurphyKG , et al. Ghrelin enhances appetite and increases food intake in humans. The Journal of Clinical Endocrinology and Metabolism2001;86(12):5992. [PMID: 11739476]">Wren 2001</a>). These diverse actions of ghrelin raise the possibility of its clinical application for conditions like anorexia, cachexia, sarcopenia, gastrointestinal diseases, cardiovascular diseases, renal and pulmonary diseases, neurodegenerative disorders, inflammatory disorders and metabolic syndromes (<a href="./references#CD012229-bbs2-0024" title="ColldénG , TschöpMH , MüllerTD . Therapeutic potential of targeting the ghrelin pathway. International Journal of Molecular Sciences2017;18(4):798. [DOI: 10.3390/ijms18040798] [PMID: 28398233]">Colldén 2017</a>; <a href="./references#CD012229-bbs2-0059" title="KhatibMN , SimkhadaP , GodeD . Cardioprotective effects of ghrelin in heart failure: from gut to heart. Heart Views2014;15(3):74-6. [DOI: 10.4103/1995-705X.144792]">Khatib 2014b</a>; <a href="./references#CD012229-bbs2-0064" title="KhatibMN , ShankarA , KirubakaranR , AghoK , SimkhadaP , GaidhaneS , et al. Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PloS One2015;10(5):e0126697. [PMID: 26016489]">Khatib 2015a</a>). It disturbs the vicious cycle of cachexia through its anabolic, orexigenic, and anti‐inflammatory effects (<a href="./references#CD012229-bbs2-0083" title="MüllerTD , NogueirasR , AndermannML , AndrewsZB , AnkerSD , ArgenteJ , et al. Ghrelin. Mol Metab2015;4(6):437–60. [DOI: 10.1016/j.molmet.2015.03.005]">Müller 2015</a>). Ghrelin regulates metabolism through activation of orexigenic neural circuits (<a href="./references#CD012229-bbs2-0083" title="MüllerTD , NogueirasR , AndermannML , AndrewsZB , AnkerSD , ArgenteJ , et al. Ghrelin. Mol Metab2015;4(6):437–60. [DOI: 10.1016/j.molmet.2015.03.005]">Müller 2015</a>). Studies have found that ghrelin is well‐tolerated and has no reported major adverse events (<a href="./references#CD012229-bbs2-0011" title="AkamizuT , KangawaK . Ghrelin for cachexia. Journal of Cachexia, Sarcopenia and Muscle2010;1(2):169-76. [PMID: 21475698]">Akamizu 2010</a>; <a href="./references#CD012229-bbs2-0005" title="HiuraY , TakiguchiS , YamamotoK , TakahashiT , KurokawaY , YamasakiM , et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer2012;118(19):4785-94. ">Hiura 2012</a>; <a href="./references#CD012229-bbs2-0064" title="KhatibMN , ShankarA , KirubakaranR , AghoK , SimkhadaP , GaidhaneS , et al. Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PloS One2015;10(5):e0126697. [PMID: 26016489]">Khatib 2015a</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>). Ghrelin agonists are being developed and tested for the treatment of anorexia/cachexia (<a href="./references#CD012229-bbs2-0016" title="BaiY , HuY , ZhaoY , YuX , XuJ , HuaZ , et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Supportive Care in Cancer2017;25(5):1651-9.">Bai 2017</a>; <a href="./references#CD012229-bbs2-0028" title="CurrowDC , SkipworthRJ . The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncology 2017 (Accessed 28 Aug 2017);13(20):1767-83. [DOI: 10.2217/fon-2017-0141]">Currow 2017</a>; <a href="./references#CD012229-bbs2-0049" title="GarciaJM , BocciaRV , GrahamCD , YanY , DuusEM , AllenS , et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncology2015;16(1):108-16. [PMID: 25524795]">Garcia 2015</a>; <a href="./references#CD012229-bbs2-0086" title="NorthrupR , KurodaK , DuusEM , BarnesSR , CheathamL , WileyT , et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Supportive Care in Cancer2013;21(9):2409-15. [PMID: 23579947]">Northrup 2013</a>; <a href="./references#CD012229-bbs2-0090" title="PietraC , TakedaY , Tazawa-OgataN , MinamiM , YuanfengX , DuusEM , et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. Journal of Cachexia, Sarcopenia and Muscle2014;5(4):329-37. [PMID: 25267366]">Pietra 2014</a>; <a href="./references#CD012229-bbs2-0104" title="TemelJS , AbernethyAP , CurrowDC , FriendJ , DuusEM , YanY , et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncology2016;17(4):519-31.">Temel 2016</a>; <a href="./references#CD012229-bbs2-0118" title="ZhangH , GarciaJM . Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opinion on Pharmacotherapy2015;16(8):1245-53. [PMID: 25945893]">Zhang 2015</a>). </p> <p>Due to these and numerous other benefits of ghrelin, pharmacological targeting of the endogenous system of ghrelin is considered a promising and valuable approach for treatment of a variety of metabolic complications including cachexia associated with cancer (<a href="./references#CD012229-bbs2-0024" title="ColldénG , TschöpMH , MüllerTD . Therapeutic potential of targeting the ghrelin pathway. International Journal of Molecular Sciences2017;18(4):798. [DOI: 10.3390/ijms18040798] [PMID: 28398233]">Colldén 2017</a>; <a href="./references#CD012229-bbs2-0053" title="HatanakaM , KonishiM , IshidaJ , SaitoM , SpringerJ . Novel mechanism of ghrelin therapy for cachexia. Journal of Cachexia, Sarcopenia and Muscle2015;6(4):393. [DOI: 10.1002/jcsm.12084]">Hatanaka 2015</a>; <a href="./references#CD012229-bbs2-0071" title="LedderoseC , KrethS , Beiras-FernandezA . Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery2011;5(1):1-6.">Ledderose 2011</a>). </p> </section> <section id="CD012229-sec-0012"> <h3 class="title" id="CD012229-sec-0012">How the intervention might work</h3> <p>Although the mechanisms of action of ghrelin have not been fully elucidated, an increase in appetite (<a href="./references#CD012229-bbs2-0027" title="Cummings DavidE . Ghrelin and the short- and long-term regulation of appetite and body weight. Physiology &amp; Behavior2006;89(1):71-84.">Cummings 2006</a>; <a href="./references#CD012229-bbs2-0116" title="WrenAM , SealLJ , CohenMA , BrynesAE , FrostGS , MurphyKG , et al. Ghrelin enhances appetite and increases food intake in humans. The Journal of Clinical Endocrinology and Metabolism2001;86(12):5992. [PMID: 11739476]">Wren 2001</a>), decrease in energy expenditure (<a href="./references#CD012229-bbs2-0048" title="GarciaJM , FriendJ , AllenS . Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer2013;21(1):129-37. [PMID: 22699302]">Garcia 2013</a>; <a href="./references#CD012229-bbs2-0082" title="MurphyMG , PlunkettLM , GertzBJ , HeW , WittreichJ , PolvinoWM , et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of Clinical Endocrinology and Metabolism1998;83(2):320-5. [PMID: 9467534]">Murphy 1998</a>), promotion of anabolic activity (<a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>), decrease in inflammation (<a href="./references#CD012229-bbs2-0032" title="DixitD , SchafferM , PyleS , CollinsD , SakthivelK , PalaniappanR , et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation2004;114(1):57-66. [PMID: 15232612]">Dixit 2004</a>; <a href="./references#CD012229-bbs2-0108" title="TsubouchiH , YanagiS , MiuraA , MatsumotoN , KangawaK , NakazatoM . Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology2014;743:1-10. [PMID: 25257464]">Tsubouchi 2014</a>), increase in growth hormone (<a href="./references#CD012229-bbs2-0047" title="GarciaJM , PolvinoWJ . Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormone &amp; IGF Research2009;19(3):267-73. [PMID: 19196529]">Garcia 2009</a>; <a href="./references#CD012229-bbs2-0058" title="KhatibMN , GaidhaneS , GaidhaneA , SyedZQ . Role of ghrelin in regulation of growth hormone secretion by ghrelin-pituitary-GH axis. International Journal of Medical Science and Public Health2014;3(4):425-9. [DOI: 10.5455/ijmsph.2014.250120141]">Khatib 2014a</a>; <a href="./references#CD012229-bbs2-0061" title="KhatibMN , GodeD , SimkhadaP , AghoK , GaidhaneS , SaxenaD , et al. Somatotropic and cardio-protective effects of ghrelin in experimental models of heart failure: a systematic review. Annals of Tropical Medicine and Public Health2014;7(1):30-42. [DOI: 10.4103/1755-6783.145008]">Khatib 2014d</a>; <a href="./references#CD012229-bbs2-0063" title="KhatibMN , GaidhaneS , GaidhaneAM , KhatibM , SimkhadaP , GodeD , et al. Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion. Journal of Clinical and Diagnostic Research2014;8(8):MC13-7. [PMID: 25302229]">Khatib 2014f</a>), control of gastrointestinal motility (<a href="./references#CD012229-bbs2-0040" title="FujinoK , InuiA , AsakawaA , KiharaN , FujimuraM , FujimiyaM . Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. The Journal of Physiology2003;550(Pt 1):227-40. [PMID: 12837928]">Fujino 2003</a>), and effects in adipose tissue (<a href="./references#CD012229-bbs2-0070" title="KosK , HarteAL , O'HarePJ , KumarS , McTernanPG . Ghrelin and the differential regulation of des-acyl (DSG) and oct-anoyl ghrelin (OTG) in human adipose tissue (AT). Clinical Endocrinology2009;70(3):383-9. [PMID: 18616714]">Kos 2009</a>) and skeletal muscle (<a href="./references#CD012229-bbs2-0091" title="PorporatoPE , FilighedduN , ReanoS , FerraraM , AngelinoE , GnocchiVF , et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. The Journal of Clinical Investigation2013;123(2):611-22. [PMID: 23281394]">Porporato 2013</a>; <a href="./references#CD012229-bbs2-0108" title="TsubouchiH , YanagiS , MiuraA , MatsumotoN , KangawaK , NakazatoM . Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology2014;743:1-10. [PMID: 25257464]">Tsubouchi 2014</a>) have been proposed. </p> <p>Ghrelin and synthetic ghrelin receptor agonists cause weight gain by increasing food intake and by food intake‐independent mechanisms (<a href="./references#CD012229-bbs2-0046" title="GarciaJ , BocciaR , GrahamC , KumorK , PolvinoW . A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. Journal of Clinical Oncology 2007 (June 20 Supplement);25(18S):9133.">Garcia 2007</a>; <a href="./references#CD012229-bbs2-0048" title="GarciaJM , FriendJ , AllenS . Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer2013;21(1):129-37. [PMID: 22699302]">Garcia 2013</a>; <a href="./references#CD012229-bbs2-0100" title="SugiyamaM , YamakiA , FuruyaM , InomataN , MinamitakeY , OhsuyeK , et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regulatory Peptides2012;178(1-3):21-8. [PMID: 22750276]">Sugiyama 2012</a>; <a href="./references#CD012229-bbs2-0107" title="TschopM , SmileyDL , HeimanML . Ghrelin induces adiposity in rodents. Nature2000;407(6806):908-13. [PMID: 11057670]">Tschop 2000</a>). Ghrelin is believed to be the only mammalian hormone that has been shown to increase appetite and food intake when delivered to humans (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0116" title="WrenAM , SealLJ , CohenMA , BrynesAE , FrostGS , MurphyKG , et al. Ghrelin enhances appetite and increases food intake in humans. The Journal of Clinical Endocrinology and Metabolism2001;86(12):5992. [PMID: 11739476]">Wren 2001</a>). Administration of ghrelin increases appetite rapidly and briefly, principally by increasing appetitive feeding behaviours and number of meals (<a href="./references#CD012229-bbs2-0027" title="Cummings DavidE . Ghrelin and the short- and long-term regulation of appetite and body weight. Physiology &amp; Behavior2006;89(1):71-84.">Cummings 2006</a>; <a href="./references#CD012229-bbs2-0036" title="FaulconbridgeLF , CummingsDE , KaplanJM , GrillHJ . Hyperphagic effects of brainstem ghrelin administration. Diabetes2003;52(9):2260-5.">Faulconbridge 2003</a>). Evidence implicates ghrelin in mealtime hunger and meal initiation (<a href="./references#CD012229-bbs2-0027" title="Cummings DavidE . Ghrelin and the short- and long-term regulation of appetite and body weight. Physiology &amp; Behavior2006;89(1):71-84.">Cummings 2006</a>). Circulating levels of ghrelin rise before meals and fall with feeding, attaining adequate concentrations to stimulate appetite and food intake (<a href="./references#CD012229-bbs2-0027" title="Cummings DavidE . Ghrelin and the short- and long-term regulation of appetite and body weight. Physiology &amp; Behavior2006;89(1):71-84.">Cummings 2006</a>). Pre‐prandial surges in ghrelin levels are possibly initiated by sympathetic nervous output while post‐prandial suppression is possibly mediated from post‐ingestive surges in insulin levels (<a href="./references#CD012229-bbs2-0026" title="CummingsDE , PurnellJQ , FrayoRS , SchmidovaK , WisseBE , WeigleDS . A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes2001;50(8):1714-9.">Cummings 2001</a>; <a href="./references#CD012229-bbs2-0027" title="Cummings DavidE . Ghrelin and the short- and long-term regulation of appetite and body weight. Physiology &amp; Behavior2006;89(1):71-84.">Cummings 2006</a>; <a href="./references#CD012229-bbs2-0107" title="TschopM , SmileyDL , HeimanML . Ghrelin induces adiposity in rodents. Nature2000;407(6806):908-13. [PMID: 11057670]">Tschop 2000</a>). As the growth hormone secretagogue receptors (GHS‐R) are expressed in vagal afferent neurons, the gastric vagus nerve may be involved in the effect of ghrelin on food intake and gastrointestinal motility (<a href="./references#CD012229-bbs2-0029" title="DateY , MurakamiN , ToshinaiK , MatsukuraS , NiijimaA , MatsuoH , et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology2002;123(4):1120-8. [PMID: 12360474]">Date 2002</a>). Ghrelin increases appetite through afferent vagal fibres to the caudal brainstem or directly to the hypothalamus (<a href="./references#CD012229-bbs2-0102" title="SuzukiK , SimpsonKA , MinnionJS , ShillitoJC , BloomSR . The role of gut hormones and the hypothalamus in appetite regulation. Endocrine Journal2010;57(5):359-72. [PMID: 20424341]">Suzuki 2010</a>). Gastric ghrelin signalling via vagal afferents suppresses the activity of the sympathetic nerves and increases the discharge of both the gastric and the vagus efferent nerves (<a href="./references#CD012229-bbs2-0041" title="FujitsukaN , AsakawaA , HayashiM , SameshimaM , AmitaniH , KojimaS , et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biological Psychiatry2009;65(9):748-59. [PMID: 19058784]">Fujitsuka 2009</a>). Ghrelin has also been shown to promote faster motor activity by activating neuropeptide Y (NPY) neurons in the brain (<a href="./references#CD012229-bbs2-0040" title="FujinoK , InuiA , AsakawaA , KiharaN , FujimuraM , FujimiyaM . Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. The Journal of Physiology2003;550(Pt 1):227-40. [PMID: 12837928]">Fujino 2003</a>). Furthermore, ghrelin modulates taste sensation (<a href="./references#CD012229-bbs2-0097" title="Shin Y-K, MartinB , KimW , WhiteCM , JiS , SunY , et al. Ghrelin is produced in taste cells and ghrelin receptor null mce show reduced taste responsivity to salty (NaCl) and sour (citric acid) tastants. PLoS One2010;5(9):e12729. [DOI: 10.1371/journal.pone.0012729]">Shin 2010</a>) and acts on the stomach to enhance gastric acid secretion (<a href="./references#CD012229-bbs2-0077" title="MasudaY , TanakaT , InomataN , OhnumaN , TanakaS , ItohZ , et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochemical and Biophysical Research Communications2000;276(3):905-8.">Masuda 2000</a>). </p> <p>Ghrelin controls mediators involved in the cachectic process (<a href="./references#CD012229-bbs2-0013" title="ArgilésJM , StemmlerB . The potential of ghrelin in the treatment of cancer cachexia. Expert Opinion on Biological Therapy2013;13(1):67-76.">Argilés 2013</a>). Ghrelin promotes weight gain and lean body mass via anti‐inflammatory actions and effects involving orexigenic peptides (<a href="./references#CD012229-bbs2-0030" title="DeBoerMD , ZhuX , LevasseurP , MeguidM , SuzukiS , InuiA , et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology2007;148(6):3004-12. [PMID: 17347304]">DeBoer 2007</a>; <a href="./references#CD012229-bbs2-0060" title="KhatibMN , KhatibM , GaidhaneS , GaidhaneA , QuaziSZ . Ghrelin for regulating appetite and energy balance: a systematic review. National Journal of Physiology, Pharmacy and Pharmacology2014;4(3):101-5. [DOI: 10.5455/njppp.2014.4.230420141]">Khatib 2014c</a>; <a href="./references#CD012229-bbs2-0065" title="KhatibMN , GaidhaneS , GaidhaneAM , SimkhadaP , ZahiruddinQS . Ghrelin-O-acyl-transferase (GOAT) as a novel metabolic regulatory enzyme. Journal of Clinical and Diagnostic Research2015;9(2):LE01-5. [PMID: 25859472]">Khatib 2015b</a>; <a href="./references#CD012229-bbs2-0072" title="Lin T-C, HsiaoM . Ghrelin and cancer progression. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer2017;1868(1):51-7.">Lin 2017</a>). Ghrelin inhibits pro‐inflammatory cytokines such as IL‐1alpha, IL‐1beta, TNF‐alpha, which may cause anorexia (<a href="./references#CD012229-bbs2-0052" title="GuneyY , OzelTU , HicsonmezA , NalcaAM , KurtmanC . Ghrelin may reduce radiation-induced mucositis and anorexia in head-neck cancer. Medical Hypotheses2007;68(3):538-40.">Guney 2007</a>; <a href="./references#CD012229-bbs2-0072" title="Lin T-C, HsiaoM . Ghrelin and cancer progression. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer2017;1868(1):51-7.">Lin 2017</a>). Animals treated with ghrelin exhibited decreased expression of IL‐1 receptor‐I transcript in the hypothalamus and brainstem and an increased expression of orexigenic peptides and NPY in the hypothalamus (<a href="./references#CD012229-bbs2-0030" title="DeBoerMD , ZhuX , LevasseurP , MeguidM , SuzukiS , InuiA , et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology2007;148(6):3004-12. [PMID: 17347304]">DeBoer 2007</a>; <a href="./references#CD012229-bbs2-0106" title="TisdaleMJ . Mechanisms of cancer cachexia. Physiological Reviews2009;89(2):381-410. [PMID: 19342610]">Tisdale 2009</a>). Ghrelin inhibits the production and prevents the increase of pro‐inflammatory cytokines released by the tumour cells (<a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>; <a href="./references#CD012229-bbs2-0032" title="DixitD , SchafferM , PyleS , CollinsD , SakthivelK , PalaniappanR , et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation2004;114(1):57-66. [PMID: 15232612]">Dixit 2004</a>; <a href="./references#CD012229-bbs2-0108" title="TsubouchiH , YanagiS , MiuraA , MatsumotoN , KangawaK , NakazatoM . Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology2014;743:1-10. [PMID: 25257464]">Tsubouchi 2014</a>). Activation of the ghrelin receptor in the central nervous system releases growth hormone, which regulates insulin‐like growth factor‐1 (IGF‐1) (<a href="./references#CD012229-bbs2-0058" title="KhatibMN , GaidhaneS , GaidhaneA , SyedZQ . Role of ghrelin in regulation of growth hormone secretion by ghrelin-pituitary-GH axis. International Journal of Medical Science and Public Health2014;3(4):425-9. [DOI: 10.5455/ijmsph.2014.250120141]">Khatib 2014a</a>; <a href="./references#CD012229-bbs2-0063" title="KhatibMN , GaidhaneS , GaidhaneAM , KhatibM , SimkhadaP , GodeD , et al. Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion. Journal of Clinical and Diagnostic Research2014;8(8):MC13-7. [PMID: 25302229]">Khatib 2014f</a>; <a href="./references#CD012229-bbs2-0111" title="VellosoCP . Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology2008;154(3):557-68. [PMID: 18500379]">Velloso 2008</a>). Growth hormone/IGF‐1 axis acts directly on bone, muscle and fat tissue, and also indirectly by producing anti‐cachectic cytokines and muscle‐restricted insulin‐like growth factor‐1 (mIGF‐1) (<a href="./references#CD012229-bbs2-0044" title="FuocoD , KilgourRD , ViganoA . A hypothesis for a possible synergy between ghrelin and exercise in patients with cachexia: biochemical and physiological bases. Medical Hypotheses2015;85(6):927-33. [PMID: 26404870]">Fuoco 2015</a>). Administration of ghrelin has been shown to prevent muscle atrophy by down‐regulating inflammation and activating protein kinase B (a protein kinase that plays a key role in apoptosis, cell proliferation, and cell migration), myogenin (a transcription factor involved in myogenesis and repair) and myoD (a protein that plays a major role in regulating muscle differentiation) (<a href="./references#CD012229-bbs2-0022" title="ChenJA , SplenserA , GuilloryB , LuoJ , MendirattaM , BelinovaB , et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle2015;6(2):132-43. [PMID: 26136189]">Chen 2015</a>). Both acytylated and unacytylated ghrelin block skeletal muscle atrophy in a growth hormone‐independent manner (<a href="./references#CD012229-bbs2-0091" title="PorporatoPE , FilighedduN , ReanoS , FerraraM , AngelinoE , GnocchiVF , et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. The Journal of Clinical Investigation2013;123(2):611-22. [PMID: 23281394]">Porporato 2013</a>). In‐vitro studies have demonstrated that ghrelin may regulate mesenchymal cell development by stimulating myogenesis (<a href="./references#CD012229-bbs2-0117" title="ZhangW , ZhaoL , MulhollandMW . Ghrelin stimulates myocyte development. Cellular Physiology and Biochemistry2007;20(5):659-64. [PMID: 17762192]">Zhang 2007</a>). Cells expressing ghrelin have demonstrated a significant increase in the differentiation of premyocytes into myocytes (<a href="./references#CD012229-bbs2-0117" title="ZhangW , ZhaoL , MulhollandMW . Ghrelin stimulates myocyte development. Cellular Physiology and Biochemistry2007;20(5):659-64. [PMID: 17762192]">Zhang 2007</a>). Short‐term administration of ghrelin at the start of cisplatin‐based chemotherapy has been shown to increase the efficiency of chemotherapy and also minimise adverse events associated with chemotherapy (<a href="./references#CD012229-bbs2-0005" title="HiuraY , TakiguchiS , YamamotoK , TakahashiT , KurokawaY , YamasakiM , et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer2012;118(19):4785-94. ">Hiura 2012</a>). </p> <p>Ghrelin analogues can be viable treatment modalities for cancer‐associated cachexia. Anamorelin, a first‐in‐class, potent, orally‐active and highly‐specific ghrelin‐receptor agonist increases food intake, body weight, lean body mass and improves quality of life in people with cancer cachexia with good tolerability and no dose‐limiting toxicities (<a href="./references#CD012229-bbs2-0016" title="BaiY , HuY , ZhaoY , YuX , XuJ , HuaZ , et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Supportive Care in Cancer2017;25(5):1651-9.">Bai 2017</a>; <a href="./references#CD012229-bbs2-0028" title="CurrowDC , SkipworthRJ . The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncology 2017 (Accessed 28 Aug 2017);13(20):1767-83. [DOI: 10.2217/fon-2017-0141]">Currow 2017</a>; <a href="./references#CD012229-bbs2-0047" title="GarciaJM , PolvinoWJ . Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormone &amp; IGF Research2009;19(3):267-73. [PMID: 19196529]">Garcia 2009</a>; <a href="./references#CD012229-bbs2-0049" title="GarciaJM , BocciaRV , GrahamCD , YanY , DuusEM , AllenS , et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncology2015;16(1):108-16. [PMID: 25524795]">Garcia 2015</a>; <a href="./references#CD012229-bbs2-0086" title="NorthrupR , KurodaK , DuusEM , BarnesSR , CheathamL , WileyT , et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Supportive Care in Cancer2013;21(9):2409-15. [PMID: 23579947]">Northrup 2013</a>; <a href="./references#CD012229-bbs2-0090" title="PietraC , TakedaY , Tazawa-OgataN , MinamiM , YuanfengX , DuusEM , et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. Journal of Cachexia, Sarcopenia and Muscle2014;5(4):329-37. [PMID: 25267366]">Pietra 2014</a>; <a href="./references#CD012229-bbs2-0104" title="TemelJS , AbernethyAP , CurrowDC , FriendJ , DuusEM , YanY , et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncology2016;17(4):519-31.">Temel 2016</a>; <a href="./references#CD012229-bbs2-0118" title="ZhangH , GarciaJM . Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opinion on Pharmacotherapy2015;16(8):1245-53. [PMID: 25945893]">Zhang 2015</a>;). Oral administration of rikkunshito, a ghrelin enhancer, increases plasma acyl ghrelin levels in humans, mice, rats and dogs (<a href="./references#CD012229-bbs2-0041" title="FujitsukaN , AsakawaA , HayashiM , SameshimaM , AmitaniH , KojimaS , et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biological Psychiatry2009;65(9):748-59. [PMID: 19058784]">Fujitsuka 2009</a>; <a href="./references#CD012229-bbs2-0042" title="FujitsukaN , AsakawaA , UezonoY , MinamiK , YamaguchiT , NiijimaA , et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translational Psychiatry2011;1:e23.">Fujitsuka 2011</a>; <a href="./references#CD012229-bbs2-0043" title="FujitsukaN , UezonoY . Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Frontiers in Pharmacology2014;5:271. [PMID: 25540621]">Fujitsuka 2014</a>; <a href="./references#CD012229-bbs2-0103" title="TakedaH , SadakaneC , HattoriT , KatsuradaT , OhkawaraT , NagaiK , et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology2008;134(7):2004-13. [PMID: 18439428]">Takeda 2008</a>, <a href="./references#CD012229-bbs2-0097" title="Shin Y-K, MartinB , KimW , WhiteCM , JiS , SunY , et al. Ghrelin is produced in taste cells and ghrelin receptor null mce show reduced taste responsivity to salty (NaCl) and sour (citric acid) tastants. PLoS One2010;5(9):e12729. [DOI: 10.1371/journal.pone.0012729]">Shin 2010</a>). Administration of RC‐1291, a ghrelin mimetic, has been shown to increase lean body mass in cachectic cancer patients (<a href="./references#CD012229-bbs2-0046" title="GarciaJ , BocciaR , GrahamC , KumorK , PolvinoW . A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. Journal of Clinical Oncology 2007 (June 20 Supplement);25(18S):9133.">Garcia 2007</a>). </p> </section> <section id="CD012229-sec-0013"> <h3 class="title" id="CD012229-sec-0013">Why it is important to do this review</h3> <p>Despite high prevalence of cancer cachexia, effective therapies are still limited and no definitive pharmacological treatment is available to address the relevant components of this syndrome (<a href="./references#CD012229-bbs2-0035" title="EspositoA , CriscitielloC , GelaoL , PravettoniG , LocatelliM , MinchellaI , et al. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treatment Reviews2015;41(9):793-7. [PMID: 26386985]">Esposito 2015</a>). There is a strong need for more effective appetite‐stimulatory therapies for people with this condition. Several studies have demonstrated positive and encouraging effects of ghrelin or growth hormone secretagogues (GHS) in people with cancer cachexia (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0080" title="MolfinoA , FormiconiA , Rossi FanelliF , MuscaritoliM . Ghrelin: from discovery to cancer cachexia therapy. Current Opinion in Clinical Nutrition and Metabolic Care2014;17(5):471-6. [PMID: 24905862]">Molfino 2014</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>). However, the safety and efficacy of ghrelin for cancer‐associated cachexia have not been systematically reviewed. There is a need to synthesise the evidence for patients, practitioners and policy makers to decide whether ghrelin can be incorporated in the management of cachexia associated with cancer and, if data permit, to explore the optimal drug programme for this group of patients. Therefore, systematic evaluation of the role of ghrelin in the treatment of cancer cachexia is warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012229-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012229-sec-0014"></div> <p>To assess the efficacy and safety of ghrelin in improving food intake, body composition and survival in people with cachexia associated with cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012229-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012229-sec-0015"></div> <section id="CD012229-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012229-sec-0017"> <h4 class="title">Types of studies</h4> <p>We planned to include randomised controlled trials (RCTs) with open or blinded assessment of outcomes. We required full journal publication with the exception of extended abstracts of otherwise unpublished clinical trials. We excluded short abstracts (usually meeting reports), non‐randomised studies, studies of experimental pain, studies done on animal models, case reports, and clinical observational studies. </p> </section> <section id="CD012229-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included cachectic patients of 18 years and over with a histological or clinical diagnosis of cancer, or meeting any of the international criteria for cancer cachexia (<a href="./references#CD012229-bbs2-0019" title="BozzettiF , MarianiL . Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN. Journal of Parenteral and Enteral Nutrition2009;33(4):361-7. [PMID: 19109514]">Bozzetti 2009</a>; <a href="./references#CD012229-bbs2-0037" title="FearonKC , VossAC , HusteadDS . Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American Journal of Clinical Nutrition2006;83(6):1345-50. [PMID: 16762946]">Fearon 2006</a>; <a href="./references#CD012229-bbs2-0038" title="FearonK , StrasserF , AnkerSD , BosaeusI , BrueraE , FainsingerRL , et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology2011;12(5):489-95. [PMID: 21296615]">Fearon 2011</a>). We included both inpatients and outpatients with any type or stage of cancer irrespective of gender or race. We included patients in any healthcare setting (including hospice, hospital, oncology centre or community). </p> </section> <section id="CD012229-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We expected studies to vary in terms of form, dose, frequency, route and duration of treatment. We included studies in which ghrelin was administered in any form, at any dose, at any frequency, by any route and for any duration, administered for improving food intake, body composition and survival, compared to placebo or no treatment or any active comparator (such as appetisers, nutritional supplements, ghrelin analogues/ghrelin mimetics, ghrelin potentiators/enhancers, etc.). Studies examining ghrelin offered as a sole intervention or in combination with another intervention were eligible. </p> <p>We had planned to undertake five comparisons. We added a sixth comparison group in this review: higher‐dose ghrelin versus lower‐dose ghrelin, as we found two studies addressing this. We thought it wiser to include this comparison rather than miss data on an intervention. </p> <p> <ol id="CD012229-list-0001"> <li> <p>Ghrelin versus placebo</p> </li> <li> <p>Ghrelin versus no treatment</p> </li> <li> <p>Ghrelin versus alternative experimental treatment modality (like appetisers, nutritional supplements, etc.) </p> </li> <li> <p>Ghrelin in combination with other treatments versus ghrelin treatment alone</p> </li> <li> <p>Ghrelin treatment versus ghrelin analogues/ghrelin mimetics (anamorelin, ipamorelin, eganamorelin, hexarelin, MK‐677, etc.) or ghrelin potentiators/enhancers (rikkunshito) </p> </li> <li> <p>Higher‐dose ghrelin versus lower‐dose ghrelin</p> </li> </ol> </p> </section> <section id="CD012229-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012229-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012229-list-0002"> <li> <p>Change in food intake as difference between baseline and the end of treatment. We planned to express this outcome as a dichotomous variable (number of participants who experienced an increase in food intake) or a continuous variable (actual change in food intake). </p> </li> <li> <p>Change in body weight as difference between baseline and at the end of treatment. We planned to express this outcome as a dichotomous variable (number of participants who experienced change in body weight) or a continuous variable (actual change in body weight). </p> </li> <li> <p>Adverse events as the number of participants who suffered an event described as an adverse event by the authors of the studies. </p> </li> </ol> </p> </section> <section id="CD012229-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012229-list-0003"> <li> <p>Change in survival measured as increase in survival in days. We planned to use hazard ratios for how many times more (or less) likely a participant was to suffer the event at a particular point in time if they received ghrelin rather than the control intervention. </p> </li> <li> <p>Change in body composition (lean body mass, fat mass) as difference between baseline and the end of treatment. We planned to express this outcome as a dichotomous variable (number of participants who experienced change in body weight) or a continuous variable (actual change in body composition). </p> </li> <li> <p>Plasma ghrelin levels as difference between baseline and the end of treatment. We planned to express this outcome as a dichotomous variable (number of participants who experienced increase in plasma ghrelin levels) or a continuous variable (actual change in plasma ghrelin levels). </p> </li> <li> <p>Change in quality of life using any validated scale (<a href="./references#CD012229-bbs2-0020" title="Centre for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Health-Related Quality of Life (HRQOL) | CDC. www.cdc.gov/hrqol/ May 2016.">CDC 2016</a>). </p> </li> </ol> </p> <p>Reporting of these outcome measures did not form part of the criteria for including studies in a review. </p> </section> </section> </section> <section id="CD012229-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012229-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases without language restrictions.</p> <p> <ol id="CD012229-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, issue 6) in the Cochrane Library </p> </li> <li> <p>MEDLINE (via Ovid) searched 1947 to 20 July 2017</p> </li> <li> <p>Embase (via Ovid) searched 1974 to 20 July 2017</p> </li> </ol> </p> <p>We used Medical subject headings (MeSH) or equivalent and text‐word terms. We obtained full‐text translations of all relevant non‐English articles and tailored the searches to individual databases. The search strategies used can be found in <a href="./appendices#CD012229-sec-0104">Appendix 1</a>. </p> </section> <section id="CD012229-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the metaRegister of controlled trials (mRCT) (<a href="http://www.controlled-trials.com/mrct" target="_blank">www.controlled-trials.com/mrct</a>), National Cancer Institute (<a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>), clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for ongoing trials in July 2017. We also searched ClinicalStudyResults.org (<a href="http://www.clinicalstudyresults.org" target="_blank">www.clinicalstudyresults.org</a>) for clinical trials. </p> <p>In addition, we checked the reference lists of reviews, retrieved articles for additional studies, and performed citation searches on key articles. We contacted study authors where necessary for additional information. We searched the British Association for Cancer Research (BACR), Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), the American Cancer Society. We contacted experts in the field for unpublished and ongoing trials to identify any additional literature related to the review. </p> </section> </section> <section id="CD012229-sec-0026"> <h3 class="title" id="CD012229-sec-0026">Data collection and analysis</h3> <section id="CD012229-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MNK, SG) independently screened the articles retrieved from the searches using the Rayyan online screening tool (<a href="./references#CD012229-bbs2-0034" title="ElmagarmidA , FedorowiczZ , HammadyH , IlyasI , KhabsaM , OuzzaniM . Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews [oral presentation]. In: Cochrane Colloquium. John Wiley &amp; Sons, 2014.">Elmagarmid 2014</a>) and determined eligibility by reading the abstract of each study identified by the search. Review authors eliminated studies that clearly did not satisfy inclusion criteria, and obtained full copies of the remaining studies. Two review authors (ZQS, AG) screened full texts of these studies independently to select relevant studies. We contacted study authors by email, if missing information impaired the study selection, to clarify the necessary information. In the event of disagreement, a third author adjudicated (AS). We did not anonymise the studies in any way before assessment. We applied no language restrictions in the selection of studies. We included a PRISMA flow chart in the full review that shows the status of identified studies (<a href="./references#CD012229-bbs2-0079" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097.">Moher 2009</a>) as recommended in Part 2, Section 11.2.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012229-bbs2-0095" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). We included studies in the review irrespective of whether measured outcome data are reported. </p> </section> <section id="CD012229-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MNK, SG) independently extracted the data using a standard form and checked for agreement before entry into Review Manager 5 (RevMan 5) (<a href="./references#CD012229-bbs2-0093" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We included information about all the primary outcomes. We collated multiple reports of the same study, so that each study rather than each report is the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to populate a table of ‘<a href="./references#CD012229-sec-0119" title="">Characteristics of included studies</a>’. </p> </section> <section id="CD012229-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>This section is taken from the PaPaS template for 'reviews'.</p> <p>Two authors (MNK, PS) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012229-bbs2-0054" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We completed a 'Risk of bias' table for each included study using the 'Risk of bias' tool in RevMan 5 (<a href="./references#CD012229-bbs2-0093" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>We assessed the following for each study.</p> <p> <ul id="CD012229-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table, computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). </p> </li> <li> <p>Blinding of participants and personnel (checking for performance bias). We assessed the methods used to blind study participants and personnel about the receipt of the intervention. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding); unclear risk of bias (study states that it was blinded but does not provide an adequate information of how it was done); high risk of bias (no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of participants of the study and personnel was attempted, but it is likely that the blinding could have been broken). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets, matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how blinding was achieved). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants did not complete the study and/or used ‘baseline observation carried forward’ analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> <li> <p>Selective outcome reporting (checking for reporting bias). We assessed studies as being at low risk of bias (the study protocol is available; or the study protocol is not available but the study reported all expected and pre‐specified outcomes); high risk of bias (the study reported one or more outcomes of interest incompletely); unclear risk of bias (the study provides insufficient information to permit judgement of ‘low risk’ or ‘high risk’). </p> </li> <li> <p>Other bias. We assessed the study as: low risk of bias (the study appears to be free of other sources of bias); unclear risk of bias (there may be a risk of bias, but there is insufficient information to judge whether risk of bias exists; or insufficient evidence that a problem under consideration will introduce bias); or high risk of bias (there is at least one important risk of bias). </p> </li> </ul> </p> </section> <section id="CD012229-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to record number of events and total number of participants in both the arms for dichotomous variables. For continuous variables we planned to record means with standard deviations and total number of participants in both the arms. We planned to summarise each study in our meta‐analysis using risk ratio (RR) or odds ratio (OR) with 95% confidence intervals (CI) for dichotomous variables and mean difference (MD) with 95% CI for continuous variables, then pool these effect estimates in a meta‐analysis. For continuous data we planned to use mean differences (MD) with 95% CI when the results were measured in the same way in different studies. We planned to use standardised mean differences (SMD) when the results obtained were conceptually the same but used different measurement scales. We planned to use a fixed‐effect model or random‐effects model to estimate the overall direction, size and consistency of an effect and obtain the change in standard deviation from CI, standard errors, t values, P values or F values (whichever was available) using the RevMan 5 calculator. If there was not enough information available to calculate the standard deviations for the changes, we planned to impute the values of the same. If the required data were not available, we planned to use a comparison of final measurements. We planned to evaluate the direction and size of the effect as well as looking at the consistency of the effect across the selected studies. We planned to consider clinically meaningful change taking into account the change in weight and appetite with a measurable entity and time span. </p> </section> <section id="CD012229-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In parallel‐group RCTs, we considered an individual participant as the unit of analysis. When incorporating cross‐over trials into a meta‐analysis, we would have followed the approach suggested by Elbourne (<a href="./references#CD012229-bbs2-0033" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>). We would have incorporated these trials by taking measurements from experimental intervention periods and measurements from control intervention periods and analysing these as if the trial were a parallel group trial of intervention versus control. If carry‐over was thought to be a problem, we would have included only data from the first period. We would have included the effect estimate of cross‐over trials in meta‐analysis using the generic inverse‐variance method. </p> </section> <section id="CD012229-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If enough studies were available; we would have carried out an intention‐to‐treat analysis. We asked for further information from the authors or manufacturers when published data were missing, incomplete or inconsistent with RCT protocols. We contacted authors by email if studies did not report the outcome measures of interest, did not describe randomisation or intention‐to‐treat analysis or had missing data. </p> </section> <section id="CD012229-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess clinical heterogeneity by using the Chi<sup>2</sup> test (P value &lt; 0.10 for statistical significance) and use the I<sup>2</sup> statistic to quantify heterogeneity. We would have regarded heterogeneity as considerable if I<sup>2</sup> was more than 75%; substantial if it was between 50% and 90%; moderate if it was between 30% and 60% and mild if less than 40% (<a href="./references#CD012229-bbs2-0031" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Deeks 2011</a>). If we had identified statistical heterogeneity (I² greater than, or equal to 50%); we would have reported it and explored possible causes by prespecified subgroup analysis, and would have applied a random‐effects model. </p> </section> <section id="CD012229-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If there would have been 10 or more included studies; we planned to conduct a funnel plot test for asymmetry to assess for any evidence of reporting bias. Additionally; we had planned to explore the possible sources of asymmetry in a funnel plot. </p> </section> <section id="CD012229-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake a meta‐analysis only if participants, interventions, comparisons and outcomes were judged to be sufficiently similar to ensure an answer that is clinically meaningful and relevant. For analysis, we planned to use <a href="./references#CD012229-bbs2-0093" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>, the statistical package provided by the Cochrane Collaboration. </p> <p>If statistical heterogeneity (I² greater than, or equal to 50%) was detected, we would have identified the sources of the heterogeneity and would have performed subsequent meta‐analysis using a random‐effects model. When meta‐analysis seemed inappropriate, we did not pool the results of the included studies, but presented a qualitative description of these studies with supporting tables. We planned to perform a meta‐analysis using a fixed‐effect model if there were sufficient and homogeneous data with consistent or comparable outcomes. </p> </section> <section id="CD012229-sec-0036"> <h4 class="title">‘Summary of findings' tables</h4> <p>We included 'Summary of findings' (SoF) tables as set out in the PaPaS author guide (<a href="./references#CD012229-bbs2-0015" title="Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. papas.cochrane.org/papas-documents (accessed on 16 August 2015).">AUREF 2012</a>) and recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012229-bbs2-0095" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). We have presented the SoF tables under the following comparisons for all of the primary outcomes: </p> <p> <ol id="CD012229-list-0006"> <li> <p>Ghrelin versus placebo</p> </li> <li> <p>Ghrelin versus an alternative experimental treatment modality</p> </li> <li> <p>Ghrelin in combination with other treatments versus ghrelin treatment alone</p> </li> <li> <p>Higher‐dose ghrelin versus lower‐dose ghrelin</p> </li> </ol> </p> <p>Two review authors (ZQS, MNQ) assessed the overall quality of the evidence for each of the primary outcome using the GRADE system (<a href="./references#CD012229-bbs2-0050" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed on September 2015). Available at gradepro.org.">GRADEpro GDT 2015</a>) and presented the findings in the 'Summary of findings' tables. In particular, we included key information concerning the quality of evidence. We planned to include the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. </p> <p>We decreased the grade rating if there was:</p> <p> <ol id="CD012229-list-0007"> <li> <p>A serious (‐1) or very serious (‐2) limitation to study quality;</p> </li> <li> <p>Important inconsistency (‐1);</p> </li> <li> <p>Some (‐1) or major (‐2) uncertainty about directness;</p> </li> <li> <p>Imprecise or sparse data (‐1);</p> </li> <li> <p>High probability of reporting bias (‐1).</p> </li> </ol> </p> <p>We have justified all decisions to downgrade the quality of studies using footnotes.</p> </section> <section id="CD012229-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to undertake subgroup analyses for form, dose, duration and route of administration of ghrelin, and for different types of cancer. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012229-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012229-sec-0038"></div> <section id="CD012229-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD012229-sec-0040"> <h4 class="title">Results of the search</h4> <p>The electronic literature searches identified 1484 potential articles. Following the removal of duplicates, we independently examined 926 papers and after initial screening, we removed 892 papers. We then independently assessed the full text of 34 potentially relevant papers. We excluded 31 papers on the basis of different population (participants other than those with cancer cachexia: n = 5, animal models: n = 11), different intervention (intervention other than ghrelin: n = 14) and different study design (n = 1). Reasons for rejecting individual studies are detailed in the '<a href="./references#CD012229-sec-0120" title="">Characteristics of excluded studies</a>' table. We identified three studies for potential inclusion (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) but none of the studies could be included in quantitative synthesis (meta‐analysis). We have presented a flow diagram detailing the selection of studies in <a href="#CD012229-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012229-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012229-sec-0041"> <h4 class="title">Included studies</h4> <p>In total, we identified three studies for inclusion (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>). The included studies were conducted in Sweden (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>), the UK (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>) and Switzerland (<a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>). All studies were randomised and double‐blind. <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> and <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> were cross‐over clinical trials while <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> was a parallel‐group clinical trial. The cross‐over clinical trials did not report washout between treatment phases. All articles were written in English. Full details can be found in the <a href="./references#CD012229-sec-0119" title="">Characteristics of included studies</a> table. </p> <section id="CD012229-sec-0042"> <h5 class="title">Participants</h5> <p>The number of participants recruited were 31 in <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>, seven in <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> and 21 in <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>. One of the seven participants failed to complete a food diary in <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>. The number of participants who completed the study were 22 in <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> and 18 in <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>. All studies included people with cancer with weight loss and anorexia. </p> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> randomised 18 men and 13 women suffering from progressive, weight‐losing gastrointestinal cancer with systemic spread into high‐dose ghrelin group (HDGG) and low‐dose ghrelin group (LDGG). The mean age of the participants in the two groups was 73 ± 2 years in HDGG and 76 ± 2 years in LDGG. The male:female ratio in the study for HDGG was 11 to 6 and for LDGG was 7 to 7. This study excluded participants aged under 40 years, people with diabetes (type I or II), people on steroid treatment, or any other treatment known or assumed to affect tumor host metabolism, as well as people receiving any nutritional support. </p> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> randomised one man and six women with cancer with sustained anorexia and weight loss. Five participants had breast cancer, one participant had colon cancer and one malignant melanoma. All participants had metastasis. Two of the seven participants in <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> were on chemotherapy. The median age of participants was 54 years. The study excluded people who had undergone surgery or radiotherapy, and were on regular use of systemic steroids or progestins. </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> randomised 17 men and three women with far‐advanced, incurable cancer and involuntary loss of weight and appetite into two groups, a higher‐dose ghrelin group (HDGG) and a lower‐dose ghrelin group (LDGG). The participants had different cancer types including: pancreatic cancer (n = 4), mesothelioma (n = 2), prostate cancer (n = 3), colorectal cancer (n = 4), stomach/oesophageal cancer (n = 2), non‐small‐cell lung carcinoma (n = 3)<br/>, urogenital cancer (n = 1), and cholangiocarcinoma (n = 1). The median age of participants in the two groups was 66 years in LDGG and 70 in HDGG. This study excluded people receiving enteral or parenteral nutrition, who had significant cause of secondary anorexia and who required new systemic antineoplastic treatment for the study period of three weeks. </p> </section> <section id="CD012229-sec-0043"> <h5 class="title">Intervention</h5> <p>One trial (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>) compared the effect of ghrelin with placebo while two trials (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) studied the effect of two different doses (higher‐dose with lower‐dose) of ghrelin. </p> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> randomised the participants into two groups: HDGG and LDGG. Participants randomised to HDGG received ~10 µg/kg daily and those randomised to LDGG received 0.5 µg/kg daily for eight weeks as once‐daily, subcutaneous injections, 30 to 45 minutes before the main daily meal. The amounts provided corresponded to 13 µg/kg daily (HDGG) or 0.7 µg/kg (LDGG) daily to account for individual body weight based on 56 doses for each group over eight weeks. </p> <p>In <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> the participants were given two infusions at least three days apart (range: 3 to 21 days), one day for ghrelin and one day for saline. Participants on chemotherapy received the first infusion at least 17 days after their chemotherapy cycle and then the same number of days after their subsequent chemotherapy cycle. Ghrelin or saline infusion was administered over 90 minutes at the rate of 5 pmoL/kg/minute. </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> conducted a two‐week trial of ghrelin infusion, four to five days after baseline at one of two dose levels HDGG and LDGG, intravenous infusion over 60 minutes, once weekly on days one and eight and placebo on days four and 11 or vice versa, that is, three days apart. The LDGG received 10 pmoL/kg/minute (approximately 2 µg/kg). After observing treatment tolerance in the LDGG participants, the investigators administered the HDGG 40 pmoL/kg/minute (approximately 8 µg/kg). Normal saline was used as placebo. </p> </section> <section id="CD012229-sec-0044"> <h5 class="title">Comparison</h5> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> compared ghrelin with placebo. Two trials (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) compared higher‐dose of ghrelin with lower‐dose of ghrelin. </p> <p>None of the trials compared ghrelin with no treatment or alternative experimental treatment modality (like appetisers, nutritional supplements, etc.) or ghrelin analogues/ghrelin mimetics (anamorelin, ipamorelin, eganamorelin, hexarelin, MK‐677, etc.) or ghrelin potentiators/enhancers (rikkunshito). None of the included trials compared ghrelin in combination with other treatments versus ghrelin treatment alone. </p> </section> <section id="CD012229-sec-0045"> <h5 class="title">Outcomes</h5> <section id="CD012229-sec-0046"> <h6 class="title">Primary outcomes</h6> <p>All the included trials assessed food intake and adverse events while none of the trials measured body weights. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> reported the food intake at baseline and after eight weeks in two groups while <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> reported the change in food intake. </p> </section> <section id="CD012229-sec-0047"> <h6 class="title">Secondary outcomes</h6> <p>None of the included trials reported data on survival. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> reported baseline and follow‐up (at eight weeks) data on body composition, plasma ghrelin levels and quality of life. <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> reported data only on plasma ghrelin levels at pre‐breakfast, at the start of infusion, and 60 minutes and 90 minutes after the start of infusion. <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> did not assess data on any of our secondary outcomes. </p> <p>In summary the three trials that met the inclusion criteria recruited 59 participants with cancer cachexia; of whom 47 were able to complete the study. All the trials were double‐blind with two trials of cross‐over design and one trial of parallel‐group design. The median age of participants across the trials ranged from 54 to 78 years. The ratio of men to women recruited in the included studies was 37 to 22. Each of the included participants suffered with various types of cancer (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>), except <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> that exclusively enrolled participants with gastrointestinal cancer. One trial (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>) compared the effect of ghrelin with placebo while two trials (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) studied the effect of two different doses (higher dose with lower dose) of ghrelin. The doses and duration of ghrelin varied between the included studies. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> administered ghrelin subcutaneously while <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> and <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> administered ghrelin intravenously. </p> </section> </section> </section> <section id="CD012229-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded <a href="./references#CD012229-bbs2-0004" title="AdachiS , TakiguchiS , OkadaK , YamamotoK , YamasakiM , MiyataH , et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology2010;138(4):1312-20. ">Adachi 2010</a>; <a href="./references#CD012229-bbs2-0005" title="HiuraY , TakiguchiS , YamamotoK , TakahashiT , KurokawaY , YamasakiM , et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer2012;118(19):4785-94. ">Hiura 2012</a>; <a href="./references#CD012229-bbs2-0007" title="TakataA , TakiguchiS , MiyazakiY , MiyataH , TakahashiT , KurokawaY , et al. Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. Annals of Surgery2015;262(2):230-6. ">Takata 2015</a>; <a href="./references#CD012229-bbs2-0008" title="TakiguchiS , HiuraY , MiyazakiY , TakataA , MurakamiK , DokiY . Clinical trial of ghrelin synthesis administration for upper GI surgery. Methods in Enzymology2012;514:409-31. ">Takiguchi 2012</a>; and <a href="./references#CD012229-bbs2-0009" title="YamamotoK , TakiguchiS , MiyataH , AdachiS , HiuraY , YamasakiM , et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery2010;148(1):31-8. ">Yamamoto 2010</a> because, although the participants suffered from cancer, they were not cachectic patients. One trial registered in a clinical trials registry (<a href="./references#CD012229-bbs2-0006" title="NCT00933361. Individual dose-escalated bi-daily subcutaneously (sc) ghrelin in cancer cachexia: a Phase I/II Study. clinicaltrials.gov2009. [NCT00933361]">NCT00933361</a>) was not an RCT and hence we excluded it. </p> </section> </section> <section id="CD012229-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>All studies were at high risk of attrition bias and bias for size of the study. Risk of bias in other domains was unclear or low (<a href="#CD012229-fig-0002">Figure 2</a>; <a href="#CD012229-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012229-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012229-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD012229-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD012229-sec-0051"> <h5 class="title">Random sequence generation</h5> <p>All studies were at low risk of selection bias for random sequence generation. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> and <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> randomised the participants using a computerised algorithm and statistical package respectively. <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> mentioned that a random allocation sequence was produced. </p> </section> <section id="CD012229-sec-0052"> <h5 class="title">Allocation concealment</h5> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> stated that participants received ghrelin according to randomisation but the study authors did not adequately provide the method of allocation concealment and so we judged it as unclear risk. <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> concealed allocation through sealed containers and so we judged it as at low risk. In <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> an independent investigator maintained randomisation procedure and opening of sealed envelopes disclosed treatment assignments and hence we judged this study as at low risk. </p> </section> </section> <section id="CD012229-sec-0053"> <h4 class="title">Blinding</h4> <p>All three included studies were double‐blind. Although <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> stated the study was 'double‐blind' the authors did not clearly describe the method of blinding. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> did not report on blinding of the outcome assessor. <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> and <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> blinded participants, investigators, and dieticians/clinicians to the type of infusion by producing identical bags containing indistinguishable liquids. </p> <p>There is unclear risk in <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>. Performance bias and detection bias appears unlikely to have occurred in <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> and <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>. </p> </section> <section id="CD012229-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We judged all three studies at high risk of attrition bias because they had substantial attrition (&gt; 10%). </p> <p>In <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> one of the seven (14.28%) participants failed to complete a food diary. In <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> three of 21 (14.28%) participants and in <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> nine of the 31 (29%) participants failed to complete the study. </p> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> did not specify the reason for attrition. In <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> two participants stopped treatment because of malignant bowel obstruction and one participant because of infection. <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> reported that interruption of treatment was either for personal reasons or because of progressive disease. None of the studies mentioned attrition due to the intervention. </p> <section id="CD012229-sec-0055"> <h5 class="title">Size of study</h5> <p>We judged all three studies (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) to be confounded by small size due to having fewer than 50 participants per treatment arm so at high risk of bias. </p> </section> </section> <section id="CD012229-sec-0056"> <h4 class="title">Selective reporting</h4> <p>The protocol of <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> was not available. <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> and <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> had registered protocols (<a href="./references#CD012229-bbs2-0056" title="ISRCTN26185223. Randomised phase I/II - study with ghrelin versus placebo for patients with cancer-related anorexia/cachexia. ISRCTN registry 2005 (accessed 28 July 2017). [DOI: 10.1186/ISRCTN26185223]">ISRCTN26185223</a>; <a href="./references#CD012229-bbs2-0085" title="NCT00681486. Ghrelin - a possible opportunity to improve appetite (phase 3). ClinicalTrials.gov2008. [NCT00681486 ]">NCT00681486</a> respectively). </p> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> did not describe the adjusted analyses, and did not present the first period results clearly in the cross‐over trial. Some outcomes, like food intake and appreciation of food were reported but with insufficient detail for the data to be included in analysis. This study provided insufficient information to permit judgement of 'low risk' or 'high risk' of bias. </p> </section> <section id="CD012229-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>We did not detect any other potential sources of bias in the included studies and hence all studies were at low risk. </p> </section> </section> <section id="CD012229-sec-0058"> <h3 class="title" id="CD012229-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD012229-tbl-0001"><b>Summary of findings 1</b> Ghrelin compared to placebo for cachexia associated with cancer</a>; <a href="./full#CD012229-tbl-0002"><b>Summary of findings 2</b> Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</a>; <a href="./full#CD012229-tbl-0003"><b>Summary of findings 3</b> Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</a>; <a href="./full#CD012229-tbl-0004"><b>Summary of findings 4</b> Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</a> </p> <section id="CD012229-sec-0059"> <h4 class="title">Comparison 1. Ghrelin versus placebo</h4> <p>One trial (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>) with seven participants compared ghrelin with placebo (<a href="#CD012229-tbl-0005">Table 1</a>; <a href="#CD012229-tbl-0006">Table 2</a>). </p> <div class="table" id="CD012229-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of results of individual studies: primary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Primary outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. "><b>Lundholm 2010</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]"><b>Neary 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. "><b>Strasser 2008</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline:</p> <p>32.5 ± 94 (SEM) kcal/kg/day</p> <p>At 8 weeks: 28.2 ± 3.8 (SEM) kcal/kg/day</p> <p>According to 4‐day schedule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 24.1 ± 3.0 (SEM) kcal/kg/day</p> <p>At 8 weeks: 25.5 ± 4.5 (SEM) kcal/kg/day</p> <p>According to 4‐day schedule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean energy intake: 9270 kJ</p> <p>(95% CI 3249 to 15,290 kJ)</p> <p>As assessed by 24‐h food diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean energy intake: 6854 kJ</p> <p>(95% CI 3634 to 10,070 kJ)</p> <p>As assessed by 24‐h food diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutritrional intake at lunch compared to baseline</p> <p>Ghrelin: 251 kcal</p> <p>Placebo: 230 kcal</p> <p>Nutritrional intake at lunch and rest of the day compared to baseline</p> <p>Ghrelin: 244 kcal</p> <p>Placebo: 156 kcal</p> <p>Monitored daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutritrional intake at lunch compared to baseline</p> <p>Ghrelin: ‐105 kcal</p> <p>Placebo: ‐17 kcal</p> <p>Nutritrional intake at lunch and rest of the day compared to baseline</p> <p>Ghrelin: 145 kcal</p> <p>Placebo: 228 kcal</p> <p>Monitored daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghrelin: 17 (increased bowel activity: 5; abdominal pain: 5; dry mouth: 3; worsening of pre‐existing neuropathy: 1; asthenia: 1; diarrhoea: 1; nausea: 1) </p> <p>Placebo: 6 (increased bowel activity: 3; dry mouth: 1; dizziness: 1; diarrhoea: 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghrelin: 7 (increased bowel activity: 3; shortness of breath: 1; sweating: 2; vomiting: 1) </p> <p>Placebo: 12</p> <p>(increased bowel activity: 5; shortness of breath: 1; nausea: 1; increased stool frequency: 1; apoplectiform deafness: 1; vomiting: 2; constipation: 1) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>SEM</b>: standard error of mean </p> </div> </div> <div class="table" id="CD012229-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of results of individual studies: secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Secondary Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. "><b>Lundholm 2010</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]"><b>Neary 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. "><b>Strasser 2008</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Body composition (lean body mass)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 44.8 ± 2.9 (SEM) kg</p> <p>At 8 weeks: 47.8 ± 2.9 (SEM) kg</p> <p>Difference over time:</p> <p>2.24 ± 0.71 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 44.3 ± 2.2 (SEM) kg</p> <p>At 8 weeks: 45.1 ± 2.8 (SEM) kg</p> <p>Difference over time:</p> <p>0.86 ± 1.18 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 1.38 kg (95% CI ‐1.32 to 4.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Body composition (fat mass)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 15.1 ± 1.9 (SEM) kg</p> <p>At 8 weeks: 13.5 ± 1.9 (SEM) kg</p> <p>Difference over time:</p> <p>‐1.3 ± 0.7 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 16.3 ± 3.0 (SEM) kg</p> <p>At 8 weeks: 12.6 ± 2.4 (SEM) kg</p> <p>Difference over time:</p> <p>‐3.7 ± 0.8 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 2.40 kg (95% CI 0.32 to 4.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Plasma ghrelin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 563 ± 90 (SEM) ng/L</p> <p>At 8 weeks: 1229 ± 501 (SEM) ng/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 3418 ± 2570 (SEM) ng/L</p> <p>At 8 weeks: 3817 ± 2997 (SEM) ng/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 min (pre‐breakfast): 531 ± 83 (SEM)</p> <p>90 min (at the start of infusion): 505 ± 90 (SEM)</p> <p>150 min (60 min after the start of infusion): 1718 ± 169 (SEM)</p> <p>180 min (90 min after the start of infusion): 1840 ± 221 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 min (pre‐breakfast): 545 ± 58 (SEM)</p> <p>90 min (at the start of infusion): 440 ± 59 (SEM)</p> <p>150 min (60 min after the start of infusion): 509 ± 97 (SEM)</p> <p>180 min (90 min after the start of infusion): 490 ± 63 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 1209.00 pmoL/L (95% CI 827.08 to 1590.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><b>Quality of Life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS anxiety</p> <p>Baseline: 4.6 ± 1.07 (SEM)</p> <p>At 8 weeks: 5.4 ± 1.6 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS anxiety</p> <p>Baseline: 8.6 ± 1.6 (SEM)</p> <p>At 8 weeks: 8.8 ± 1.3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances between the two groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS depression</p> <p>Baseline: 5.7 ± 0.9 (SEM)</p> <p>At 8 weeks: 6.8 ±1.2 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS depression</p> <p>Baseline: 7.6 ±1.4 (SEM)</p> <p>At 8 weeks: 9.3 ± 1.9 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference ‐2.50 (95% CI ‐6.90 to 1.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 PCS</p> <p>Baseline: 30 ± 3 (SEM)</p> <p>At 8 weeks: 27 ± 3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 PCS</p> <p>Baseline: 35 ± 3 (SEM)</p> <p>At 8 weeks: 30 ± 2 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference ‐3.00 (95% CI ‐10.07 to 4.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 MCS</p> <p>Baseline: 40 ± 3 (SEM)</p> <p>At 8 weeks: 41 ± 3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 MCS</p> <p>Baseline: 30 ± 2 (SEM)</p> <p>At 8 weeks: 34 ± 4 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval<br/><b>HADS</b> : Hospital Anxiety and Depression Scale<br/><br/><b>SEM</b> : standard error of mean<br/><b>SF‐36 MCS</b> : 36‐item Short Form Health Survey Mental Component Scale<br/><b>SF‐36 PCS</b>: 36‐item Short Form Health Survey Physical Component Scale </p> </div> </div> <p>We assessed the quality of evidence using GRADE for all primary outcomes in this comparison as very low. We downgraded the evidence for study limitations (due to high risk of attrition bias and biases confounded by small size) and imprecision or due to lack of data. See <a href="./full#CD012229-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012229-sec-0060"> <h5 class="title">Primary outcomes</h5> <section id="CD012229-sec-0061"> <h6 class="title">1. Food intake</h6> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> reported the effect on food intake after intravenous administration of a single dose of 5 pmoL/Kg/minute of ghrelin as assessed by 24‐hour food diary (<a href="#CD012229-tbl-0005">Table 1</a>). The energy intake at baseline differed amongst the participants. This trial reported a 31% increase in energy intake after administration of ghrelin. Over a day, mean energy intake after ghrelin administration was 9270 kJ (95% CI 3249 to 15,290) as compared to 6854 kJ (95% CI 3634 to 10,070) after saline administration (P = 0.09). The trial also found a 23% increase in perceived pleasantness of the meal (as assessed by visual analogue score) on the day of administration of ghrelin as compared to day of administration of saline. Appetite increased in all participants who received ghrelin. </p> <p>We downgraded the quality of evidence using GRADE once for study limitations due to high risk of attrition bias and biases confounded by small size. Only seven participants participated in the study and the loss to follow‐up was more than 10%. The evidence was further downgraded twice for imprecision due to sparse data and low participant numbers. These data were insufficient to be meaningful. </p> </section> <section id="CD012229-sec-0062"> <h6 class="title">2. Body weight</h6> <p>This study did not report the effect of ghrelin on body weight.</p> <p>We reported the quality of evidence using GRADE for body weight as very low, downgraded three times due to a lack of data. </p> </section> <section id="CD012229-sec-0063"> <h6 class="title">3. Adverse events</h6> <p>No adverse events were observed in <a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> in either of the intervention groups (<a href="#CD012229-tbl-0005">Table 1</a>). </p> <p>We rated the quality of evidence using GRADE for adverse events as very low, downgraded once for study limitations due to high risk of attrition bias and bias confounded by small size, and downgraded twice for imprecision due to sparse data and low event rate. </p> </section> </section> <section id="CD012229-sec-0064"> <h5 class="title">Secondary outcomes</h5> <section id="CD012229-sec-0065"> <h6 class="title">1. Survival</h6> <p>This study did not report on survival.</p> </section> <section id="CD012229-sec-0066"> <h6 class="title">2. Body composition</h6> <p>Body composition was not assessed in this study.</p> </section> <section id="CD012229-sec-0067"> <h6 class="title">3. Plasma ghrelin levels</h6> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a> assessed plasma ghrelin levels in seven participants before breakfast, at the start of infusion, 60 minutes after the start of infusion and 90 minutes after the start of infusion. They presented the data as mean with standard error of the mean (SEM) in pmoL/litre. We converted the SEM into SD with the help of the RevMan 5 calculator and found that after 60 minutes of infusion, plasma ghrelin was higher in the ghrelin group compared to the placebo group (MD 1209.00 pmoL/L, 95% CI 827.08 to 1590.92; one study; 7 participants). We could not analyse the change in plasma ghrelin levels or number of participants who experienced an increase in plasma ghrelin levels due to insufficient information (<a href="#CD012229-tbl-0006">Table 2</a>). </p> </section> <section id="CD012229-sec-0068"> <h6 class="title">4. Quality of life</h6> <p>This study did not assess quality of life.</p> </section> </section> </section> <section id="CD012229-sec-0069"> <h4 class="title">Comparison 2. Ghrelin versus no treatment</h4> <p>None of the trials compared ghrelin with no treatment</p> </section> <section id="CD012229-sec-0070"> <h4 class="title">Comparison 3. Ghrelin versus alternative experimental treatment modality</h4> <p>None of the trials compared ghrelin with an alternative experimental treatment modality, like appetisers, nutritional supplements, etc. We judged the quality of the evidence using GRADE to be very low, downgraded three times due to a lack of data. See <a href="./full#CD012229-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD012229-sec-0071"> <h4 class="title">Comparison 4. Ghrelin in combination with other treatments versus ghrelin treatment alone </h4> <p>None of the trials compared ghrelin in combination with other treatments with ghrelin treatment alone. </p> <p>We judged the quality of the evidence using GRADE to be very low, downgraded three times due to a lack of data. See <a href="./full#CD012229-tbl-0003">summary of findings Table 3</a> </p> </section> <section id="CD012229-sec-0072"> <h4 class="title">Comparison 5. Ghrelin treatment versus ghrelin analogues/ghrelin mimetics</h4> <p>None of the trials compared ghrelin with ghrelin analogues/ghrelin mimetics, like anamorelin, ipamorelin, eganamorelin, hexarelin, MK‐677, etc., or ghrelin potentiators/enhancers like rikkunshito. </p> </section> <section id="CD012229-sec-0073"> <h4 class="title">Comparison 6. Higher dose of ghrelin versus lower dose of ghrelin</h4> <p>Two trials (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) compared a higher dose of ghrelin with a lower dose of ghrelin. Neither of the studies reported data on body weight and survival. Because of the different study designs (parallel and cross‐over) and great diversity in the treatment provided (dosage, route of administration, frequency and duration of treatment) in the included trials; meta‐analysis seemed inappropriate and we did not pool the results. However, we have presented a narrative summary of each of these studies with supporting tables (<a href="#CD012229-tbl-0005">Table 1</a>; <a href="#CD012229-tbl-0006">Table 2</a>). </p> <p>We assessed the quality of evidence using GRADE for all primary outcomes in this comparison as very low. The evidence was downgraded for study limitations (due to high risk of attrition bias and biases confounded by small size) and imprecision or due to lack of data. See <a href="./full#CD012229-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD012229-sec-0074"> <h5 class="title">Primary outcomes</h5> <section id="CD012229-sec-0075"> <h6 class="title">1. Food intake</h6> <p>In <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> food intake (as assessed according to four‐day record) did not differ between 12 participants on higher‐dose and 10 participants on lower‐dose ghrelin over time. Appetite was higher in participants on higher‐dose ghrelin as compared with participants on lower‐dose ghrelin (<a href="#CD012229-tbl-0005">Table 1</a>). </p> <p>In <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>, there were no differences in nutritional intake compared to baseline when participants received ghrelin or placebo. In 11 participants on higher‐dose ghrelin, nutritional intake at lunch compared to baseline was 251 kcal. In nine participants on lower‐dose ghrelin, nutritional intake at lunch compared to baseline was ‐105 kcal (<a href="#CD012229-tbl-0005">Table 1</a>). </p> <p>The quality of evidence was downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size. Forty participants participated in these two studies and each study had more than 10% loss to follow‐up. The evidence was further downgraded twice for imprecision due to sparse data and low participant numbers. </p> </section> <section id="CD012229-sec-0076"> <h6 class="title">2. Body weight</h6> <p>Neither of the included studies (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) reported the effect of ghrelin on body weight. </p> <p>We reported the level of evidence for body weight as very low, downgraded three times due to a lack of data. </p> </section> <section id="CD012229-sec-0077"> <h6 class="title">3. Adverse events</h6> <p>No objective adverse effects were reported with higher‐dose or lower‐dose ghrelin in <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> (<a href="#CD012229-tbl-0005">Table 1</a>). </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> reported 17 adverse events in 11 participants on upper‐dose and seven adverse events in nine participants on lower‐dose ghrelin. Adverse events observed with higher dose of ghrelin were increased bowel activity (n = 5), abdominal pain (n = 5), dry mouth (n = 3), worsening of pre‐existing neuropathy (n = 1), asthenia (n = 1), diarrhoea (n = 1) and nausea (n = 1). Adverse events observed with lower dose of ghrelin were increased bowel activity (n = 3), shortness of breath (n = 1), sweating (n = 2) and vomiting (n = 1) (<a href="#CD012229-tbl-0005">Table 1</a>). Although the study reported 13 serious adverse events, only one, transient apoplectiform deafness, was supposedly related to the treatment. </p> <p>We rated the quality of evidence for adverse events as very low, downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size, and downgraded twice for imprecision due to sparse data and low participant numbers. </p> </section> </section> <section id="CD012229-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD012229-sec-0079"> <h6 class="title">1. Survival</h6> <p>Neither of the included studies (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) reported this outcome. </p> </section> <section id="CD012229-sec-0080"> <h6 class="title">2. Body composition</h6> <section id="CD012229-sec-0081"> <p><b>Lean body mass</b></p> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> reported that difference over time in lean body mass was more with higher‐dose ghrelin (2.24 ± 0.71 (SEM)) compared to lower‐dose ghrelin (0.86 ± 1.18 (SEM)) (<a href="#CD012229-tbl-0006">Table 2</a>). </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> did not measure lean body mass. </p> </section> <section id="CD012229-sec-0082"> <p><b>Fat mass</b></p> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> reported that higher‐dose ghrelin reduced the loss of whole‐body fat. There was a total of 31 participants in this trial. Whole‐body fat loss was less pronounced in participants who were receiving higher‐dose ghrelin as compared with lower‐dose ghrelin (P &lt; 0.04). The difference over time in fat mass was ‐1.3 ± 0.7 (SEM) with higher‐dose ghrelin and ‐3.7 ± 0.8 (SEM) with lower‐dose ghrelin (<a href="#CD012229-tbl-0006">Table 2</a>). </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> did not measure fat mass. </p> </section> </section> <section id="CD012229-sec-0083"> <h6 class="title">3. Plasma ghrelin levels</h6> <p>In <a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>, there were significant differences in the baseline plasma ghrelin values 563 ± 90 (SEM) ng/L in higher‐dose ghrelin group and 3418 ± 2570 (SEM) ng/L in lower‐dose ghrelin group. After eight weeks of treatment, plasma ghrelin increased in both the groups 1229 ± 501 (SEM) ng/L in higher‐dose ghrelin group and 3817 ± 2997 (SEM) ng/L in lower‐dose ghrelin group (<a href="#CD012229-tbl-0006">Table 2</a>). </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> did not measure plasma ghrelin levels. </p> </section> <section id="CD012229-sec-0084"> <h6 class="title">4. Quality of life</h6> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a> assessed health‐related quality of life using the 36‐item Short Form Health Survey (SF‐36) and the Hospital Anxiety and Depression Scale (HADS) in 31 participants. There were baseline imbalances in HADS anxiety score and SF‐36 Mental component scale between the two groups. Health‐related quality of life did not differ over time between participants in higher‐dose and lower‐dose ghrelin groups. However, participants receiving higher‐dose ghrelin had less anxiety and scored better for mental health at inclusion compared to participants receiving lower‐dose ghrelin (<a href="#CD012229-tbl-0006">Table 2</a>). </p> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a> did not assess quality of life. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012229-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012229-sec-0085"></div> <section id="CD012229-sec-0086"> <h3 class="title" id="CD012229-sec-0086">Summary of main results</h3> <p>We included three studies reporting data from 47 participants (59 randomised initially), aged 54 to 78 years, comparing ghrelin with placebo, or higher‐dose ghrelin with lower‐dose ghrelin. None of the included studies assessed data on body weight and survival. One trial (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>), which compared ghrelin with placebo, found that ghrelin improved food intake and had no adverse events. Two studies (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>; <a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>), which compared higher‐dose ghrelin with lower‐dose ghrelin, individually showed that participants on higher‐dose ghrelin had greater improvement in food intake, body composition, plasma ghrelin and quality of life. Reporting of adverse events provided no information. All the included studies were at high risk of attrition bias and other bias due to small size. Risk of bias in other domains were mostly low or unclear. </p> <p>Due to differences in study designs (parallel and cross‐over) and diversity in the treatment provided (dosage, route of administration, frequency and duration of treatment), we could not undertake meta‐analysis. We are unable to make any judgement about the efficacy or safety of ghrelin for improving food intake, body composition and survival in people with cachexia associated with cancer. We found insufficient evidence that using ghrelin showed changes in food intake. We found no evidence that using ghrelin alone or in combination made any difference to body weight. No conclusions could be reached about adverse events. The limited amount of information means that we cannot draw any conclusions. </p> <p>The evidence we found was very low quality and the true effect is very likely to be substantially different from that reported. The very low GRADE judgement was based on lack of data, methodological limitations of the included studies, and overall small study size (<a href="./full#CD012229-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012229-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012229-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012229-tbl-0004">summary of findings Table 4</a>). </p> <p>Results of the studies available are insufficient to draw any conclusions regarding safety and efficacy of ghrelin in treating people with cancer cachexia. The evidence is insufficient to support or refute its use. </p> </section> <section id="CD012229-sec-0087"> <h3 class="title" id="CD012229-sec-0087">Overall completeness and applicability of evidence</h3> <p>This review highlights our lack of knowledge about the effectiveness of ghrelin for cancer cachexia. We found three studies that met our inclusion criteria. The three included studies randomised 59 participants and 47 participants completed the study. One cross‐over trial (<a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]">Neary 2004</a>) compared ghrelin with placebo while two trials, one cross‐over (<a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. ">Strasser 2008</a>) and one parallel trial (<a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. ">Lundholm 2010</a>) compared different doses of ghrelin (higher‐dose versus lower‐dose). We did not find studies that compared ghrelin versus no treatment or alternative experimental treatment modality or ghrelin analogues/ghrelin mimetics/ghrelin potentiators/enhancers; or in combination with other treatments. Outcomes of interest to people with cancer cachexia, such as improvement in food intake, body weight and survival were not adequately reported. </p> <p>There is a small body of evidence that we were able to include in this review, which limits the conclusions we can draw. We found insufficient evidence that using ghrelin showed improvement in food intake. We found no evidence that using ghrelin alone or in combination made any difference to body weight. There is insufficient evidence to be able to conclude that ghrelin is effective and has no major adverse events in people with cancer cachexia. </p> <p>Limited data from very few included studies with small sample sizes in this systematic review confirms the need for further large randomised controlled trials with long‐term follow‐up focusing on evaluation of efficacy of ghrelin as well as adverse events associated with use of ghrelin in people with cancer cachexia. We look forward to such trials being available for inclusion in future updates of this review. </p> </section> <section id="CD012229-sec-0088"> <h3 class="title" id="CD012229-sec-0088">Quality of the evidence</h3> <p>The quality of evidence for all our primary outcomes was very low, meaning we have little confidence in the effect estimate and the true effect may be substantially different from the estimate of the effect. In general, the assessment of the quality of the included studies was too limited by deficiencies in terms of quality of methodology and reporting of adequate data, and small study size to allow reasonable conclusions to be drawn. Sample sizes of all included studies were likely to be under‐powered to find a true effect, as they involved fewer than 50 participants. </p> <p>The quality of evidence for ghrelin versus placebo across all our primary outcomes was very low, due to too few data and due to the fact that the number of events was too small to be meaningful (<a href="./full#CD012229-tbl-0001">summary of findings Table 1</a>). </p> <p>The quality of evidence for ghrelin versus no treatment or alternative experimental treatment modalities or ghrelin in combination with other treatments or ghrelin analogues/ghrelin mimetics/ghrelin potentiators across our primary outcomes was very low, due to no available data (<a href="./full#CD012229-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012229-tbl-0003">summary of findings Table 3</a>). </p> <p>The quality of evidence for higher‐dose ghrelin versus lower‐dose ghrelin for all our primary outcomes was very low, due to high risk of attrition bias and biases confounded by small size, too few data and the number of events too small to be meaningful (<a href="./full#CD012229-tbl-0004">summary of findings Table 4</a>). </p> <p>This review does not provide a reliable indication of the likely effect. As a result, there is no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </section> <section id="CD012229-sec-0089"> <h3 class="title" id="CD012229-sec-0089">Potential biases in the review process</h3> <p>We have estimated that the potential bias in the review process is low. The search was as comprehensive as possible. The evaluation of trials for inclusion was done in pairs. None of the authors of this review were involved in any of the included or excluded studies. Furthermore, none have any commercial or any other conflicts of interest regarding ghrelin. We are confident that we have included all relevant published studies. We have attempted to reduce bias in the review process by performing data extraction and assessing study quality independently. However, the possibility remains that we may have missed studies which have not been published. </p> <p>We undertook the review in line with the recommendations of Cochrane as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD012229-bbs2-0055" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011b</a>) </p> <p>The authors of this review are from different disciplines with different focuses (e.g. public health, biostatistics, clinical medicine, nutrition). We consider this internal variety of expertise to be a strength of this review and made use of it by duplicating procedures during the entire review process when possible. </p> </section> <section id="CD012229-sec-0090"> <h3 class="title" id="CD012229-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>This is the first systematic review of ghrelin for the management of cachexia associated with cancer. Numerous studies have tried to summarise the applicability of ghrelin for cancer cachexia but have not have used a systematic approach (<a href="./references#CD012229-bbs2-0013" title="ArgilésJM , StemmlerB . The potential of ghrelin in the treatment of cancer cachexia. Expert Opinion on Biological Therapy2013;13(1):67-76.">Argilés 2013</a>; <a href="./references#CD012229-bbs2-0048" title="GarciaJM , FriendJ , AllenS . Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer2013;21(1):129-37. [PMID: 22699302]">Garcia 2013</a>; <a href="./references#CD012229-bbs2-0080" title="MolfinoA , FormiconiA , Rossi FanelliF , MuscaritoliM . Ghrelin: from discovery to cancer cachexia therapy. Current Opinion in Clinical Nutrition and Metabolic Care2014;17(5):471-6. [PMID: 24905862]">Molfino 2014</a>). </p> <p>We identified one non Cochrane systematic review (<a href="./references#CD012229-bbs2-0096" title="SeverS , WhiteDL , GarciaJM . Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. Endocrine-Related Cancer2016;23(9):R393-409.">Sever 2016</a>) involving human and animal in vivo studies to assess the safety and efficacy of ghrelin/ghrelin analogues on the risk, presence, or growth of tumours in people with cancer or animal models of cancer, irrespective of the presence or absence of cachexia. The authors could not undertake any meta‐analysis but suggested that the safety profile of ghrelin and ghrelin analogues may be favourable for the treatment of cachexia in people with cancer. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012229-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/urn:x-wiley:14651858:media:CD012229:CD012229-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_t/tCD012229-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012229-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/urn:x-wiley:14651858:media:CD012229:CD012229-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_t/tCD012229-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012229-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/urn:x-wiley:14651858:media:CD012229:CD012229-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_t/tCD012229-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/media/CDSR/CD012229/image_n/nCD012229-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012229-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ghrelin compared to placebo for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin compared to placebo for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cachexia associated with cancer </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not known</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study reported, "31% increase in energy intake with ghrelin infusion"</p> <p>Too few data to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No data available.</p> <p>No evidence to support or refute the use of ghrelin in people with cancer cachexia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study reported, "No side effects were observed"</p> <p>Too few data and number of events too small to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size.<br/><sup>2</sup>Downgraded twice for imprecision due to sparse data and low participant numbers.<br/><sup>3</sup>Downgraded three times: in circumstances where there were no data reported for an outcome, we reported the level of evidence as very low with no evidence to support or refute the use of ghrelin in people with cancer cachexia.<br/><sup>4</sup>Downgraded twice for imprecision due to sparse data, low participant numbers and number of events too small to be meaningful. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ghrelin compared to placebo for cachexia associated with cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012229-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin<br/><b>Comparison</b>: alternative experimental treatment modality (like appetisers, nutritional supplements, etc.) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alternative experimental treatment modality</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ghrelin compared to alternative experimental treatment modality for cachexia associated with cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012229-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : ghrelin in combination with other treatments<br/><b>Comparison</b>: ghrelin treatment alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin treatment alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ghrelin in combination with other treatments</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ghrelin in combination with other treatments compared to ghrelin treatment alone for cachexia associated with cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012229-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: people with cancer cachexia </p> <p><b>Settings</b> : hospital<br/><b>Intervention</b> : higher‐dose ghrelin<br/><b>Comparison</b>: lower‐dose ghrelin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lower‐dose ghrelin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with higher‐dose ghrelin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Too few data to be meaningful</p> <p>Because of the differences in study design and diversity in the treatment provided we did not pool results in a meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. No evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Too few data to be meaningful</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval <b>N/A</b>: not applicable </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for study limitations due to high risk of attrition bias and biases confounded by small size.<br/><sup>2</sup>Downgraded twice for imprecision due to low participant numbers.<br/><sup>3</sup>In circumstances where there were no data reported for an outcome, we report the level of evidence as 'very low' with no evidence to support or refute the use of ghrelin in people with cancer cachexia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Higher‐dose ghrelin compared to lower‐dose ghrelin for cachexia associated with cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012229-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of results of individual studies: primary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Primary outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. "><b>Lundholm 2010</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]"><b>Neary 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. "><b>Strasser 2008</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Food intake</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline:</p> <p>32.5 ± 94 (SEM) kcal/kg/day</p> <p>At 8 weeks: 28.2 ± 3.8 (SEM) kcal/kg/day</p> <p>According to 4‐day schedule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 24.1 ± 3.0 (SEM) kcal/kg/day</p> <p>At 8 weeks: 25.5 ± 4.5 (SEM) kcal/kg/day</p> <p>According to 4‐day schedule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean energy intake: 9270 kJ</p> <p>(95% CI 3249 to 15,290 kJ)</p> <p>As assessed by 24‐h food diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean energy intake: 6854 kJ</p> <p>(95% CI 3634 to 10,070 kJ)</p> <p>As assessed by 24‐h food diary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutritrional intake at lunch compared to baseline</p> <p>Ghrelin: 251 kcal</p> <p>Placebo: 230 kcal</p> <p>Nutritrional intake at lunch and rest of the day compared to baseline</p> <p>Ghrelin: 244 kcal</p> <p>Placebo: 156 kcal</p> <p>Monitored daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutritrional intake at lunch compared to baseline</p> <p>Ghrelin: ‐105 kcal</p> <p>Placebo: ‐17 kcal</p> <p>Nutritrional intake at lunch and rest of the day compared to baseline</p> <p>Ghrelin: 145 kcal</p> <p>Placebo: 228 kcal</p> <p>Monitored daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghrelin: 17 (increased bowel activity: 5; abdominal pain: 5; dry mouth: 3; worsening of pre‐existing neuropathy: 1; asthenia: 1; diarrhoea: 1; nausea: 1) </p> <p>Placebo: 6 (increased bowel activity: 3; dry mouth: 1; dizziness: 1; diarrhoea: 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghrelin: 7 (increased bowel activity: 3; shortness of breath: 1; sweating: 2; vomiting: 1) </p> <p>Placebo: 12</p> <p>(increased bowel activity: 5; shortness of breath: 1; nausea: 1; increased stool frequency: 1; apoplectiform deafness: 1; vomiting: 2; constipation: 1) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>SEM</b>: standard error of mean </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of results of individual studies: primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012229-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of results of individual studies: secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Secondary Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0001" title="LundholmK , GunneboL , KörnerU , Iresjö B-M, EngströmC , HyltanderA , et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer2010;116(8):2044-52. "><b>Lundholm 2010</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0002" title="NearyNM , SmallCJ , WrenAM , LeeJL , DruceMR , PalmieriC , et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism2004;89(6):2832-6. [PMID: 15181065]"><b>Neary 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012229-bbs2-0003" title="StrasserF , Lutz TA , Maeder MT , ThuerlimannB , BuecheD , TschöpM , et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer2008;98(2):300-8. "><b>Strasser 2008</b> </a> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Higher‐dose ghrelin group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lower‐dose ghrelin group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Body composition (lean body mass)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 44.8 ± 2.9 (SEM) kg</p> <p>At 8 weeks: 47.8 ± 2.9 (SEM) kg</p> <p>Difference over time:</p> <p>2.24 ± 0.71 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 44.3 ± 2.2 (SEM) kg</p> <p>At 8 weeks: 45.1 ± 2.8 (SEM) kg</p> <p>Difference over time:</p> <p>0.86 ± 1.18 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 1.38 kg (95% CI ‐1.32 to 4.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Body composition (fat mass)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 15.1 ± 1.9 (SEM) kg</p> <p>At 8 weeks: 13.5 ± 1.9 (SEM) kg</p> <p>Difference over time:</p> <p>‐1.3 ± 0.7 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 16.3 ± 3.0 (SEM) kg</p> <p>At 8 weeks: 12.6 ± 2.4 (SEM) kg</p> <p>Difference over time:</p> <p>‐3.7 ± 0.8 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 2.40 kg (95% CI 0.32 to 4.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Plasma ghrelin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 563 ± 90 (SEM) ng/L</p> <p>At 8 weeks: 1229 ± 501 (SEM) ng/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline: 3418 ± 2570 (SEM) ng/L</p> <p>At 8 weeks: 3817 ± 2997 (SEM) ng/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 min (pre‐breakfast): 531 ± 83 (SEM)</p> <p>90 min (at the start of infusion): 505 ± 90 (SEM)</p> <p>150 min (60 min after the start of infusion): 1718 ± 169 (SEM)</p> <p>180 min (90 min after the start of infusion): 1840 ± 221 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 min (pre‐breakfast): 545 ± 58 (SEM)</p> <p>90 min (at the start of infusion): 440 ± 59 (SEM)</p> <p>150 min (60 min after the start of infusion): 509 ± 97 (SEM)</p> <p>180 min (90 min after the start of infusion): 490 ± 63 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference 1209.00 pmoL/L (95% CI 827.08 to 1590.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><b>Quality of Life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS anxiety</p> <p>Baseline: 4.6 ± 1.07 (SEM)</p> <p>At 8 weeks: 5.4 ± 1.6 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS anxiety</p> <p>Baseline: 8.6 ± 1.6 (SEM)</p> <p>At 8 weeks: 8.8 ± 1.3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances between the two groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS depression</p> <p>Baseline: 5.7 ± 0.9 (SEM)</p> <p>At 8 weeks: 6.8 ±1.2 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HADS depression</p> <p>Baseline: 7.6 ±1.4 (SEM)</p> <p>At 8 weeks: 9.3 ± 1.9 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference ‐2.50 (95% CI ‐6.90 to 1.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 PCS</p> <p>Baseline: 30 ± 3 (SEM)</p> <p>At 8 weeks: 27 ± 3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 PCS</p> <p>Baseline: 35 ± 3 (SEM)</p> <p>At 8 weeks: 30 ± 2 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean difference ‐3.00 (95% CI ‐10.07 to 4.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 MCS</p> <p>Baseline: 40 ± 3 (SEM)</p> <p>At 8 weeks: 41 ± 3 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 MCS</p> <p>Baseline: 30 ± 2 (SEM)</p> <p>At 8 weeks: 34 ± 4 (SEM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Baseline imbalances</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>CI</b> : confidence interval<br/><b>HADS</b> : Hospital Anxiety and Depression Scale<br/><br/><b>SEM</b> : standard error of mean<br/><b>SF‐36 MCS</b> : 36‐item Short Form Health Survey Mental Component Scale<br/><b>SF‐36 PCS</b>: 36‐item Short Form Health Survey Physical Component Scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of results of individual studies: secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012229.pub2/full#CD012229-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012229.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012229-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012229-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012229-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012229-note-0009">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012229\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012229\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012229\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012229\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012229\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012229.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012229.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012229.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012229.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012229.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726782263"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012229.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726782266"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012229.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9c0e2c179368',t:'MTc0MDcyNjc4Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 